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Medication adherence is of utmost importance in predicting health outcomes 
across numerous chronic conditions, particularly HIV/AIDS. Highly active antiretroviral 
therapy (HAART) to treat HIV/AIDS requires high levels of adherence to maintain viral 
suppression, which is crucial for optimal HIV treatment and prevention. One of the most 
significant patient-level barriers to medication adherence is depressive symptoms. Even 
at subclinical levels, depressive symptoms predict nonadherence above and beyond other 
relevant psychosocial factors. Despite the focus on depressive symptoms as a reliable and 
powerful predictor of nonadherence, few studies have sought to test potential 
mechanisms underlying this relationship, which is an important step to advance our 
understanding of how depression affects adherence to inform intervention efforts. The 
current study utilized early behavioral theories of depression (Lewinsohn, 1974; Ferster, 
1973) to select potential mediators that may be relevant to both depression and 
adherence. Specifically, we tested the key components of these models, (1) goal-directed 




potential mediators of the relationship between depressive symptoms and medication 
adherence among HIV positive individuals in substance abuse treatment (n = 73). We 
examined adherence to HAART as well as adherence to other daily medications using a 
combination of self-report assessments (% of doses missed over past four days, frequency 
of doses missed across common reasons for nonadherence) and viral load. Greater levels 
of punishment mediated a positive relationship between clinician-rated depressive 
symptoms and greater frequency of missed doses across common reasons for 
nonadherence. Activation and positive reinforcement were unrelated to adherence or viral 
load in this sample. Findings suggest the importance of punishment in explaining the 
relationship between depression and medication nonadherence. Individuals with elevated 
depressive symptoms may perceive greater negative consequences related to medications 
(e.g., side effects, stigma) and may be less likely to overcome barriers necessary for 
optimal adherence. If findings continue to replicate, this may suggest a need to target 
punishment in HIV prevention and treatment, for instance in the context of integrated 
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Chapter 1: Introduction 
Importance of Medication Adherence in HIV 
 
 Medication adherence is of utmost importance across numerous chronic medical 
conditions, and arguably most impactful on health outcomes and disease progression in 
HIV/AIDS. Indeed, highly active antiretroviral therapy (HAART) for the treatment of 
HIV/AIDS has substantially improved clinical outcomes, but only in the presence of 
consistent HAART use and nearly perfect rates of HAART adherence (Crum et al., 
2006). Indeed, living with HIV/AIDS requires careful attention to medication adherence.  
“Medication adherence” is defined in numerous ways in the literature, but most 
broadly refers to either medication doses missed completely (e.g., in the past four days, 
week, month, etc.) or doses taken earlier or later than the prescribed time (i.e., outside the 
appropriate time window). HAART regimens include a variety of medication types, 
including most commonly nucleoside reverse-transcriptase inhibitors (NRTIs), protease 
inhibitors (PIs), or more recently developed boosted PIs; all are taken daily, most often 
individuals are instructed to take medications twice daily (~67%) with a smaller 
percentage of individuals taking medications once daily or some three times daily 
(Genberg et al., 2011). Although medication instructions differ across drug classes, the 
majority are instructed to be taken at the same time each day, most preferably within a 
specific time window (e.g., 2-4 hours). Further, individuals are often taking other 
medication regimens for co-occurring medical and psychiatric comorbidities in addition 
to managing HAART regimens, which also require high levels of adherence (Cruess, 





How is it assessed? Medication adherence is assessed using a variety of methods, 
and given the document difficulties in accurately measuring adherence, researchers tend 
to compare different methods of adherence measurement, typically using self-report 
methods, an objective assessment (i.e., electronic pill caps), and HIV viral load as a 
clinical criterion of HAART adherence (Arnsten et al., 2001; Liu, Golin, Miller, Hays, 
Beck, & Sanandaji, 2001; Reynolds, 2004). Viral load has been most commonly selected 
as a clinical criterion, as it is considered the most proximal biological indicator of 
HAART adherence, with only the most optimal rates of HAART adherence leading to an 
undetectable amount of virus in the blood stream (i.e., <50 copies/mL) (Bangsberg et al., 
2001; Bangsberg, 2006).  
Numerous researchers have suggested that relying on solely one data source when 
measuring medication adherence will likely ‘misrepresent the “true” rate of adherence’ 
(Reynolds, 2004), as electronic pill caps tend to underestimate levels of adherence, while 
self-report measures tend to overestimate adherence. Further, electronic pill caps are 
often only utilized for a single medication and may not capture adherence across all pills 
in a regimen (Bova, Fennie, Knafl, Dieckhaus, Watrous, & Williams, 2005). There is 
some evidence that a summary or composite measure that combines two or more 
measures of adherence is more strongly related to clinical response than either measure 
alone (e.g., Farley, Hines, Musk, Ferrus, & Tepper, 2003; Liu et al., 2001); however, 
numerous other reviews have cautioned against summarization of data, as it may result in 
a loss of information of adherence patterns and a loss of power when investigating 
changes in adherence over time (Choo, Rand, Inui, Lee, Canning, & Platt, 2001; 





Although newly developed modeling strategies and technologies continue to be 
developed to accurately assess adherence (e.g., Haberer et al., 2010), the most widely 
used measure of adherence remains self-report due to issues of cost and logistical 
feasibility (Simoni, Kurth, Pearson, Pantalone, Merrill, & Frick, 2006). Given the notable 
limitations of self-report assessment, including primarily the overestimation of adherence 
levels due to social desirability biases, it is recommended to utilize an additional measure 
of adherence that is more objective in nature, such as electronic pill cap technology or a 
biological indicator of therapeutic impact (i.e., HIV viral load; Reynolds, 2004). 
Although these three methods may be highly correlated, utilizing separate indicators of 
this difficult to assess behavior may be advantageous (Reynolds, 2004; Simoni et al., 
2006). Additionally, regarding self-report assessment, guidelines have been developed to 
minimize social desirability biases, including framing questions to assume nonadherence, 
wording questions to normalize nonadherence, querying for reasons for nonadherence (as 
an alternative to asking directly about missed doses), as well as comparing self-report to 
other adherence measures to check for reliability (Miller & Hays, 2000; Simoni et al., 
2006).  
Why is it important, and how much “adherence” is enough? For HAART 
specifically, the minimum level of adherence required for clinical effectiveness is 
somewhat unclear and also may differ across drug classes; however, there is a well-
established consensus that it is necessary to take a high proportion of HAART doses to 
maintain suppression of viral replication. Paterson and colleagues (2000) demonstrated 
that 78% of individuals who were ≥ 95% adherent showed suppressed viral load (to ≤ 





adherence, such that if individuals were < 70% adherent, only 19% showed viral load ≤ 
400 copies/mL. Even dropping to only 90-95% adherence, only 45% of individuals in 
this category achieved suppressed viral load (Paterson et al., 2000). More recently, 
evidence points to more potent drugs that have been developed (i.e., boosted PIs) as 
being more forgiving of nonadherence, such that they can suppress viral replication at 
more moderate levels of adherence (Bangsberg, 2006). However, high levels of 
adherence are still necessary (e.g., with boosted PIs, 92% of individuals achieved viral 
suppression with 78 to 93% adherence; Shuter, Sarlo, Kanmaz, Rode, & Zingman, 2007).  
Do patients adhere? The strongest predictor of viral suppression is adherence, 
yet the proportion of individuals who achieve optimal adherence is often very small, 
ranging from 30% (Paterson et al., 2000) to as low as 4% (Golin et al., 2002). An 
important recently published study indicated that only 19% of all HIV-infected 
individuals nationwide showed undetectable viral load (i.e., <50 copies/mL), which is in 
a large part due to suboptimal adherence to HAART (Gardner, McLees, Steiner, del Rio, 
& Burman, 2011). A recent worldwide survey compared rates of adherence across 
countries and indicated that rates of adherence were the lowest in North America; 55% of 
patients in North America reported missing at least one dose in the past 30 days (Nachega 
et al., 2011). However, even when very high levels of adherence are not possible, a 10% 
increase in adherence can be associated with medically significant improvements in HIV 
outcomes (e.g., decreases in viral load; Bangsberg et al., 2001; Liu, Miller, Golin, Wu, 
Wenger, & Kaplan, 2006). Thus, although near perfect adherence is the optimal goal, 





Implications of nonadherence. Nonadherence and inconsistent patterns of 
adherence (e.g., interruptions in treatment, breaks from medication) have been associated 
with increased likelihood of production of medication-resistant HIV strains, greater 
health complications, failure to achieve full viral suppression (Bangsberg et al., 2001), 
and increased risk of death (Garcia de Olalla, Knobel, Carmona, Guelar, Lopez-Colomes, 
& Cayla, 2002). Although other pharmacological and biological causes can lead to drug 
resistance, missed HAART doses is the leading contributor to resistance. Drug resistance 
in particular is a significant public health issue, as individuals with persistent 
nonadherence will likely become resistant to existing medications and can also spread 
drug resistant strains of HIV to uninfected HIV individuals (Wainberg & Friedland, 
1998). Indeed, adherence has important prevention implications, as recent work has also 
demonstrated that regular use of HAART by HIV positive individuals (as well as HIV 
negative individuals using Pre-Exposure Prophylaxis [PrEP]) may prevent HIV 
transmission, but these effects are only found among individuals with high levels of 
adherence (Cohen, 2010; Grant et al., 2010; Karim et al., 2010).  
Monitoring adherence to other medications when patients are not receiving HAART 
In addition to HAART nonadherence, lack of any HAART use (i.e., not being on 
HAART even when medically indicated) is also a critical factor that contributes to poor 
HIV/AIDS health outcomes and continued transmission of the virus. Despite the 
accessibility of HAART in the U.S., many patients are still not taking HAART; the 
Centers for Disease Control and Prevention report (CDC, 2011a) estimated that only 45% 
of individuals diagnosed with HIV are using HAART in the U.S. This may be due to a 
variety of reasons, including structural barriers and psychological factors (i.e., fear of side 





& Das, 2010). In particular, low-income, minority substance users have consistently been 
identified as a high risk group for not using HAART (Chander et al., 2009). Importantly, 
these groups may be at highest risk for HAART nonadherence once they do initiate a 
regimen, which, as stated earlier, has important implications related to future resistance to 
HAART regimens and poor health outcomes. As such, it has become an important 
priority for providers to monitor adherence to other daily medication regimens for 
patients who are not using HAART.  
Supporting this perspective, adherence to other forms of medication (e.g., for 
other chronic medical conditions, psychotropic medication) or even placebo pills, has 
been shown to be one of the strongest predictors of future HAART adherence among 
individuals not receiving HAART (Cruess et al., 2012; Wagner, 2003). Indeed, adherence 
to other forms of medication tend to be highly correlated with HAART adherence (e.g., r 
= .49, p < .001; Wagner, 2003) and predict HAART adherence above and beyond other 
commonly related factors (e.g., recent medical appointment attendance, cognitive 
functioning, unstable housing, adherence self-efficacy; Wagner, 2003). Particularly 
among substance using populations, monitoring adherence to other forms of medication 
or placebo medication is common place to assess readiness for HAART, as providers 
may avoid prescribing substance users HAART to avoid numerous health risks that are 
likely if individuals do not adhere (Wagner, 2003). Studies have demonstrated that high 
adherence to other medications (i.e., psychotropic medication) is very strongly associated 
with high HAART adherence (Cruess et al., 2012; Horberg et al., 2008). In sum, 





HAART is extremely important given that these individuals may be at greatest risk for 
poor adherence once they initiate a HAART regimen (Chander et al., 2009).  
Factors Associated with Medication Nonadherence 
  
Numerous factors have been identified as being associated with medication 
nonadherence among HIV/AIDS patients; reviews on this topic have identified over 200 
variables related to adherence, which are consistent across HAART adherence 
specifically as well as other forms of medication (Fogarty, Roter, Larson, Burke, 
Gillespie, & Levy, 2002). Fogarty et al. (2002) conducted a review of published and 
abstract reports on this topic and provided a comprehensive overview of factors related to 
medication nonadherence. This review grouped factors according to the following 
categories: factors related to the treatment regimen (regimen complexity, side effects), 
treatment- and medication-related attitudes and beliefs (e.g., fear and skepticism of the 
regimen, mistrust, myths of treatment effects), overall HIV disease attitudes (e.g., 
pessimism about HIV, worsening disease outcomes), scheduling demands (work, daily 
routine, mealtime dosing challenges), cognitive factors (difficulty concentrating, 
forgetfulness, inadequate information about medication), as well as many social and 
psychological factors such as psychiatric comorbidity (depression, anxiety, and substance 
use), and social climate (social support, confidentiality fears, disclosure). Institutional- 
and provider-specific variables were also identified as predictors of adherence, such as 
access to medication and health care, as well as provider support throughout treatment, 
perceived caring, and open communication with one’s provider. Individual characteristics 
tested in relation to adherence included physical health status (hospitalization, 





assessment), low socioeconomic status (education level, literacy, income, housing status, 
minority status), and demographic information (age, gender).  
Similar categories of factors related to medication nonadherence have been 
identified in other reviews (e.g., Chesney, 2003; Reynolds, 2004) and include treatment 
characteristics (complexity, side effects), patient-related factors (lifestyle characteristics, 
psychosocial issues, psychological functioning, social support, health beliefs, substance 
use), factors related to the patient-provider relationship, and overall healthcare system-
related factors (access to care, medications, informational resources). Regarding the 
patient-related factors, a high percentage of individuals simply forget their medication or 
have difficulty understanding regimen instructions (Chesney et al., 2000a) or have 
interfering psychosocial issues such as substance abuse, depression, stress, hopelessness, 
negative feelings, and poor social support (Chesney, Morin, & Sherr, 2000b; Gordillo, 
Del Amo, & Soriano, 1999; Holzemer et al., 1999; Paterson et al., 2000). These factors 
are relevant to HAART adherence specifically as well as adherence to other forms of 
medication among individuals with HIV (Cruess et al., 2012; Wagner, 2003). Of these 
factors, the most significant predictors of nonadherence that have been shown to be less 
easily mitigated through intervention include depression and stress (Chesney et al., 
2000b; Gordillo et al., 1999; Paterson et al., 2000). Other studies examining 
psychological predictors of adherence have consistently demonstrated the important roles 
of depression, social support, treatment adherence self-efficacy, and substance use (Catz, 
Kelly, Bogart, Benotsch, & McAuliffe, 2000; Eldred, Wu, Chaisson, & Moore, 1998; 
Kalichman, Ramachandran, & Catz, 1999; Singh, Squier, Sivek, Wagener, Nguyen, & 





 Despite numerous factors identified as being related to medication nonadherence, 
there are few agreed upon variables that consistently predict adherence. Although the 
field has been able to identify correlates of nonadherence, experts in the field 
acknowledge that nonadherence is still poorly understood (Reynolds, 2004). Null 
findings are evident across almost all variables that report predictive associations, most 
notably for sociodemographic variables (gender, ethnicity, age, education, income, 
employment, and housing status) as well as substance use (Fogarty et al., 2002; Holzemer 
et al., 1999). As noted by Reynolds (2004), why an individual would not take their 
medication even when it may be lifesaving “belies simple explanations or 
demographics,” and few factors reliably predict adherence.  
As such, numerous researchers have pointed to the pressing need to focus 
research efforts on enhancing our understanding of those few predictors that consistently 
impact medication adherence. One such reliable predictor of nonadherence is depression. 
Depression has been shown to predict nonadherence across chronic medical conditions 
(DiMatteo, Lepper, & Croghan, 2000); among HIV positive individuals, depression 
predicts nonadherence above and beyond other reliable predictors, such as social support 
(Safren et al., 2001), stigma (DiIorio et al., 2009) and other psychiatric conditions 
(Waldrop-Valverde & Valverde, 2005). Further, depression as a barrier to adherence has 
received significant empirical and clinical attention given (1) its high prevalence among 
individuals with HIV/AIDS and (2) the link between depression and later HIV disease 
progression. In sum, as outlined in detail in the next section, depression is one of the few 
reliable predictors of adherence, and its impact on HIV outcomes represents a significant 





Depression is a Consistent Predictor of Medication Nonadherence 
Although reviews have pointed to the fact that it is difficult to reliably predict 
medication adherence, the presence of depressive symptoms has been found to be one of 
the most consistent and significant predictors (Catz et al., 2000; Gordillo et al., 1999; 
Holzemer et al., 1999). The significant impact of depression on medication adherence is 
consistent with other types of chronic conditions; depression has been noted to be a 
barrier to adherence for patients with hypertension (Kim, Han, Hill, Rose, & Roary, 
2003), coronary artery disease (Carney, Freedland, Eisen, Rich, & Jaffe, 1995), diabetes 
(Ciechanowski, Katon, Russo, & Hirsch, 2003), and kidney failure (Everett, Brantley, 
Sletten, Jones, & McKnight, 1995). Across these chronic conditions, depressed patients 
have been shown to be three times more likely to be nonadherent to medical regimens 
than non-depressed counterparts (see DiMatteo et al., 2000 for a meta-analysis).  
Impact of depression on HAART adherence. Regarding HAART specifically, 
numerous studies have demonstrated depressive symptoms to have a powerful and 
consistent impact on adherence. A large multicenter trial found that 39% of nonadherent 
HIV positive individuals had clinically elevated depressive symptoms (assessed using the 
Montgomery-Asberg Depression Rating Scale [MADRS]) vs. only 17% of adherent 
individuals, and that only lower MADRS scores were associated with nonadherence to 
HAART in a final model (Starace et al., 2002). In another large-scale multi-site trial, 
Horberg and colleagues (2008) examined the effects of depression on HAART adherence 
among 3,359 patients at two large health maintenance organizations. In their sample, 
42% of all patients had a depression diagnosis, and untreated depression was significantly 
associated with decreased odds of achieving ≥ 90% adherence. Another recent cohort 





that those that developed depressive symptoms during the study period had worse 
adherence at a follow up (45.1% vs. 25.95%) vs. those who had not developed significant 
depressive symptoms; individuals with depressive symptoms were approximately two 
times more likely to have poor adherence over time (Kacanek, Jacobson, Spiegelman, 
Wanke, Isaac, & Wilson, 2010). 
Depressive symptoms have been shown to be related to poor medication 
adherence over and above other psychosocial variables commonly related to adherence, 
such as social support, adherence self-efficacy, HIV-related attitudes (Safren, Otto, & 
Worth, 1999), neurocognitive impairment (Ammassari et al., 2004), patient satisfaction 
with provider, and stigma (DiIorio et al., 2009) as well as other psychiatric conditions 
and environmental factors (Waldrop-Valverde & Valverde, 2005). Studies have also 
sought to compare the impact of different psychiatric disorders on adherence; for instance 
Vranceanu et al. (2008) compared the impact of posttraumatic stress disorder (PTSD) and 
depression on HAART adherence and found that only depression contributed significant 
unique variance in predicting HAART adherence, suggesting a primary role of depression 
as a psychiatric disorder associated with poor adherence. Even at sub-threshold levels, 
depressive symptoms have a strong relationship with nonadherence; in a sample of 
substance users in methadone maintenance, a one-point increase in clinician-rated 
depressive symptoms (on the seven-point depression Clinical Global Impression Scale) 
was associated with a 75% increase in the odds of HAART nonadherence. Thus, even a 
moderate depression rating according to this scale would indicate almost a fivefold 
increase in the odds of nonadherence as compared to when no depressive symptoms are 





High prevalence of depression in HIV. The impact of depression on adherence is 
particularly relevant to HIV given the extremely high prevalence of depression among 
individuals living with HIV. Depression is the most common psychological disorder 
among individuals with HIV (Bing et al., 2001; Chesney, 2003); estimates suggest that 
approximately 37% of patients infected with HIV meet criteria for a current depressive 
episode and 50% for a past history of major depression (e.g., Asch et al., 2003; Bing et 
al., 2001). Depression is thought to emerge following notification of initial HIV diagnosis 
and during periods of disease progression, as well as due to more constant stressors 
related to social, occupational, and sexual rejection, and “restrictions in activities that 
give meaning to life” (Starace et al., 2002).  
A meta-analysis comparing HIV sero-positive individuals with HIV sero-negative 
individuals revealed HIV-infected individuals were almost twice as likely to be 
diagnosed with major depression compared to HIV sero-negative patients (Ciesla & 
Roberts, 2001). Morrison et al. (2002) found that major depression was four times higher 
in HIV-seropositive women compared to HIV-seronegative women. Further, the chances 
of acquiring depression are even higher among ethnic minorities and those living in 
poverty (Hasin, Goodwin, Stinson & Grant, 2005; Moneyham, Sowell, Seals, & Demi, 
2000); rates of major depression have been shown to reach 72% among low-income, 
minority substance users with HIV (Berger-Greenstein, Cuevas, Brady, Trezza, 
Richardson, & Keane, 2007). 
Consequences of depression and medication adherence: HIV disease 
progression. The effects of depression on HAART adherence have clear clinical 





HIV disease outcomes (largely due to its impact on medication adherence). Paterson et al. 
(2000) found a 40% increased risk of virologic failure in patients with active depression. 
Relatedly, depression has been associated with shorter survival among HIV positive 
individuals on HAART, such that individuals with depressive symptoms have shown to 
be almost six times more likely to die than adherent patients with no depressive 
symptoms (Lima et al., 2007). Another 7-year longitudinal study identified HIV positive 
individuals with depressive symptoms to be two times more likely to die compared with 
those with limited or no depressive symptoms (Ickovics et al., 2001). The impact of 
depression on HAART adherence has warranted significant empirical and clinical 
attention given its link to later HIV disease progression and increased risk of mortality 
(Gore-Felton & Koopman, 2008; Leserman et al., 2002).  
How Does Depression Impact Medication Adherence? 
  
Despite the focus on depression as a reliable and powerful predictor of medication 
nonadherence across chronic health conditions and among individuals with HIV 
specifically, few studies have sought to test potential mechanisms underlying the 
relationship between depression and medication nonadherence.  A recent meta-analysis 
and review of the relationship between depression and HAART adherence (n = 35,029; 
95 independent samples) noted that “although many studies have examined "whether" 
depression is associated with treatment nonadherence in HIV/AIDS, none of the included 
studies examined "how" depression is related to nonadherence” (Gonzalez et al., 2011a, 
p. 186). To date, numerous studies have focused on testing medication adherence as a 
mediator of the relationship between depression and disease progression (Gore-Felton & 





how depression impacts adherence—have not been tested adequately, and further, not in 
a high-risk sample of low-income, minority substance users. This recently published 
meta-analysis (Gonzalez et al., 2011a) pointed specifically to the need for “more research 
that examines the potential mechanisms linking depression and treatment nonadherence 
in HIV/AIDS to develop more focused interventions,” (p. 186). Relatedly, another 
recently published commentary also noted that there is a pressing need to identify 
“underlying psychological processes” that account for the impact of depression on 
HAART adherence as well as other forms of medication adherence in HIV (Kagee, 
2012).   
 Importance of understanding the impact of depression on adherence. 
Identifying potential mechanisms underlying the relationship between depression and 
medication adherence can advance our understanding of how depression interferes with 
adherence in order to inform intervention efforts. This is particularly important currently, 
as there has been an increasing focus in the field on developing integrated treatments 
(i.e., to target both depression and adherence simultaneously; Daughters, Magidson, 
Schuster, & Safren, 2010; Safren et al., 2009; 2012; Soroudi et al., 2008). Improving our 
understanding of how depression affects adherence has the potential to increase the 
effectiveness of these interventions as well as to better match intervention efforts to 
patient needs, particularly for patients with psychiatric comorbidity. This is sorely needed 
given that less than 20% of individuals in the U.S. living with HIV/AIDS demonstrate 
optimal health outcomes (Gardner et al., 2011), increasing risks of mortality, drug 
resistance, and continued HIV transmission (Cohen, 2010; Grant et al., 2010; Karim et 





al., 2007). In sum, although depressive symptoms have been identified as a prevalent and 
powerful barrier to adherence, particularly among substance users, no studies to date 
(e.g., n = 35,029; 95 independent samples included in a recent meta-analysis; Gonzalez et 
al., 2011a) have examined how depression is related to nonadherence, which is crucial “to 
develop more focused interventions” (Gonzalez et al., 2011a; p. 186). 
Potential Mediators of the Relationship between Depression and Adherence 
Selecting potential behavioral mediators of the relationship between depression 
and adherence requires a careful consideration of theory and relevance to medication 
adherence. Additionally, research has pointed to the importance of identifying behavioral 
mediators in advancing our understanding of adherence, particularly given that behavior 
can be more easily altered with intervention, and secondly, regarding HAART adherence 
specifically, the most commonly cited reasons for nonadherence are behavioral (Chesney, 
2003; Palmer, Salcedo, Miller, Winiarski, & Arno, 2003). Thus, consideration of 
potential mediators of the relationship between depression and adherence in the current 
proposal stems closely from behavioral theories of depression that are also closely 
relevant to existing research on medication adherence.  
Behavioral theories of depression. Behavioral models of depression may offer 
insight into identifying potential behavioral mediators of the relationship between 
depression and medication adherence. Early behavioral theories of depression developed 
by Lewinsohn (1974) and Ferster (1973) suggest that depression is characterized by a few 
key components: (1) goal-directed activation; (2) the degree of positive reinforcement 
available in one’s environment; and (3) the extent to which an individual experiences 





Regarding the first component, goal-directed activation, behavioral theories of 
depression posit that depression results from a change in specific behavioral patterns, 
such that individuals engage in fewer goal-directed or meaningful activities/behaviors, 
either in terms of quantity (the number or intensity of these behaviors) or the quality 
(diversity of types of activities, associated meaning or purpose; Ferster, 1973; 
Lewinsohn, 1974). This is supported by early work using the Pleasant Events Schedule 
(PES; MacPhillamy & Lewinsohn, 1971), which demonstrated that depressed, non-
depressed, psychiatric, and normal controls all exhibited a positive relationship between 
mood level and frequency of pleasant activities (Lewinsohn & Graf, 1973; Lewinsohn & 
Libet, 1972). Depressed individuals engaged in fewer pleasant activities and reported less 
pleasure from these activities (Lewinsohn & Graf, 1973; MacPhillamy & Lewinsohn, 
1971); in particular, depressed individuals lacked engagement in interpersonal behaviors, 
thereby suggesting they may have been receiving less social reinforcement (Lewinsohn & 
Shaffer, 1971). 
The second and third components, the degree to which an individual experiences 
reinforcement and punishment in one’s environment, are related to a combination of 
factors. Recent evidence suggests that the probability of experiencing reinforcement may 
be closely related to a person’s ability to obtain or elicit reinforcement, including 
necessary skills (e.g., social skills) to engage in behaviors that may be reinforced. 
Further, this likelihood is influenced by the availability of potentially reinforcing events, 
one’s history of being exposed to punishing or aversive experiences, as well as the 
presence of suppressors or punishers in one’s current environment. In sum, obtaining 





the probability of reinforcement in one’s environment (Carvalho et al., 2011; Lewinsohn, 
1974; Lewinsohn, Sullivan, & Grosscup, 1980).   
Relevance of Behavioral Theories of Depression to Medication Adherence in 
HIV/AIDS 
 
The main components of behavioral theories of depression (Ferster, 1973; 
Lewinsohn, 1974), (1) goal-directed activation, (2) positive reinforcement in one’s 
environment, and (3) punishment in one’s environment, may hold particular relevance to 
medication adherence in HIV/AIDS. Although these relationships have not yet been 
tested directly (i.e., between goal-directed activation and adherence, or positive 
reinforcement/punishment in one’s environment and adherence), other lines of evidence 
suggest that these changes in behavior- and reinforcement-related patterns may be 
associated with medication adherence. Next, we review lines of evidence suggesting that 
these core components of behavioral theories of depression may hold particular relevance 
to understanding medication adherence in HIV/AIDS. 
Goal-directed activation and medication adherence. Numerous lines of 
research have suggested that one’s patterns of activity engagement may be particularly 
important in predicting medication adherence (Chesney et al., 2000a; Gifford, Bormann, 
& Shively, 2000; Roberts, 2000; Wenger et al., 1999). Lifestyle characteristics and 
“patterns of regular behaviors and activities” (Wagner & Ryan, 2004), including changes 
in daily routine and ability to fit a regimen into a daily routine, have consistently been 
identified as important factors related to medication adherence, including HAART, other 
forms of medication, and even placebos (Chesney et al., 2000a; Gifford et al., 2000; 





demonstrated that engaging in regular, daily activities predicted medication adherence 
over and above other factors commonly related to adherence (gender, diagnostic status, 
patient-provider relationship, psychological stress, and perceived treatment efficacy).
1
 
Further, this may also depend on the type of activity, such as social-related 
activities or employment. Wagner & Ryan (2004) found that regarding social activities, 
“active social networks” seem to interfere with medication adherence, yet social support 
is consistently identified as a facilitator to adherence. Depression-related research has 
suggested that reduced social interaction in particular may limit opportunities for 
emotional and practical support necessary for adherence (Starace et al., 2002). Mixed 
findings have also been identified regarding how employment impacts adherence 
(Chesney et al., 2000a; Wagner & Ryan, 2004). To date, this line of work has largely 
been limited to the practical and logistical aspects of activity engagement (e.g., routine, 
location of activities). Studies rarely have also captured the quality of these activities, for 
instance the purpose of the activities (e.g., goal-directed nature) or reward associated with 
these activities, which may be important in clarifying mixed findings. 
Positive reinforcement in one’s environment and medication adherence. 
Various lines of evidence suggest that positive reinforcement in one’s environment may 
be important to inspire continued motivation for self-care behaviors. For instance, studies 
focusing on contingency management approaches to medication adherence have 
identified that other forms of reinforcement may be necessary for continued adherence, as 
medication adherence provides little positive reinforcement for immediate behavior; 
rather, individuals are more likely experience aversive consequences (e.g., side effects, 
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others noticing them taking medication, reminder of HIV status; Chesney, 2003; Chesney 
et al., 2000a). As such, other forms of positive reinforcement in one’s environment may 
be necessary to drive continued motivation for self-care and overall motivation to 
“engage in self-care activities designed to prolong one’s life” (Berger-Greenstein et al., 
2007; Ryan & Wagner, 2003). Holzemer et al. (1999) examined predictors of adherence 
across diverse clinical settings in seven U.S. cities (n = 420) and found that the only 
significant predictors of adherence were self-reported depressive symptoms and one 
specific component of a quality of life assessment labeled “cherishing the environment” 
(measured using a 38-item scale of quality of life among individuals with HIV/AIDS; 
Wilson, Hutchinson, & Holzemer, 1997). The cherishing the environment subscale was 
composed of items related to “having a meaningful life,” “feeling comfortable and well-
cared for,” “using time wisely,” and “taking time for important things.” This element of 
quality of life—how an individual interacts with his/her environment in a meaningful 
way—is closely tied to behavioral theories of depression and the types of behaviors that 
are typically reduced among individuals with depression. Yet, this has not yet been tested 
as a mechanism underlying the relationship between depression and medication 
adherence.  
Punishment in one’s environment and medication adherence. One’s history of 
being exposed to punishing or aversive experiences and the presence of 
punishers/suppressors in one’s environment also may be relevant to medication 
adherence. Exposure to punishing or aversive experiences is closely linked to an external 
locus of control of reinforcement, referring to the degree to which individuals expect that 





characteristics (Rotter, 1975). Indeed, there is great overlap between these two constructs, 
such that individuals with an external locus of control are more likely to report 
experiencing punishing or aversive experiences and believe their behavioral choices will 
not lead to subsequent reinforcement (Hiroto, 1974; Rotter, 1966). An external locus of 
control is strongly implicated in depression (Benassi, Sweeney, & Dufour, 1988) and 
health-related behaviors; numerous lines of research have demonstrated that one’s locus 
of control predicts patterns of adherence across chronic conditions, such as diabetes 
(Schlenk & Hart, 1984) and hypertension (Stanton, 1987), and evidence also has 
suggested locus of control may be related to medication adherence and HIV-related self-
care (Aversa & Kimberlin, 1996; Evans, Ferrando, Rabkin, & Fishman, 2000). As such, 
the specific component of Lewinsohn’s theory related to one’s perception of being 
exposed to punishing or aversive experiences, which has been strongly linked to 
depression, may also be implicated in adherence.  
 In sum, although the specific components of early behavioral theories of 
depression have not been tested in relation to medication adherence, numerous lines of 
evidence suggest their relevance to adherence. Further, these components of Lewinsohn’s 
theory may be potential mediators of the relationship between depression and medication 
adherence, which to date, has not been tested. 
Substance Users as High Risk Group to Target for HIV, Depression 
Understanding the relationship between depression and medication adherence 
may be most critical to substance abusing HIV positive populations, as HIV positive 
substance users have been shown to display the highest rates of depressive symptoms 
(Berger-Greenstein et al., 2007). Both substance use and HIV have been shown to 





Moneyham et al., 2000). Among low-income, minority HIV positive substance users 
living in urban areas, research has indicated the extremely high rates of major depression 
(i.e., reaching up to 72%; Berger-Greenstein et al., 2007). Further, even sub-threshold 
levels of depressive symptoms are highly correlated with nonadherence in this 
population; for instance, a one-point increase in clinician-rated symptoms was associated 
with a 75% increase in the odds of HAART nonadherence among active substance users 
in methadone maintenance (Gonzalez et al., 2011b). 
In addition to high rates of depression in this group and the demonstrated impact 
of depressive symptoms on adherence, low-income minority substance users living in 
urban areas are also an important group to target because they bear the burden of a more 
recent shift in the HIV/AIDS epidemic. Recent epidemiological statistics on the 
HIV/AIDS epidemic indicate that African Americans account for almost half of people 
living with HIV in the U.S. and nearly half of new infections in the U.S. (CDC, 2011b); 
further, examining incidence rates by transmission category from 1985 through 2009, 
heterosexual contact is the only mode of HIV transmission that has continued to be on the 
rise (CDC, 2011b), which is largely among African Americans and suggested to be 
intertwined with a substance using lifestyle (i.e., sex with an injection drug user or 
exchange of sex for drugs or money common among crack/cocaine users; CDC, 2007). In 
the District of Columbia specifically, which reports the highest rate of new HIV/AIDS 
cases in the U.S. (120 AIDS diagnoses per 100,000 per population, five times greater 
than the other states reporting the highest rates of HIV/AIDS in the U.S; CDC, 2011b), 
the most notable increase in new HIV cases has been among substance users, specifically 





cases are African Americans, who represent 95% of cumulative cases in this population 
(Ngamsnga & Wright-Andoh, 2004). Heterosexual contact (i.e., sex with a person with or 
at high risk for HIV infection, primarily injection drug users, and exchange of sex for 
drugs or money particularly among crack/cocaine users), is the leading mode of 
transmission among African Americans in Washington D.C. (32.4%; DC Department of 
Health, 2010) and a leading driver of the continued epidemic in the area (Kuo et al., 
2011). Finally, this is also a very important group to target based on disparities in health 
outcomes; low-income, minority, HIV positive substance users often demonstrate poor 
HIV health outcomes, primarily due to poor HAART adherence or not using HAART at 
all (Chander et al., 2009).  
In sum, across the U.S. as well as in D.C. specifically, HIV incidence has shifted 
from primarily high rates among men who have sex with men (MSM) to more “socially 
vulnerable” and “disenfranchised populations,” including low-income minority groups 
with comorbid mental health conditions and other types of substance use disorders 
(beyond only injection drug use) such as crack/cocaine dependence (Mellins et al., 2009). 
Individuals suffering from depression, substance use problems, and HIV follow a more 
chronic and treatment-resistant course than those with only one disorder (Cook, Grey, & 
Burke-Miller, 2004) and warrant particular attention given the changing epidemic.  
Current Study 
 
The current study aimed to improve our understanding of potential mechanisms 
underlying the impact of depression on medication nonadherence among low-income 
HIV positive substance users. We used a theoretically-driven approach to test behavioral 





Lewinsohn and Ferster’s early behavioral models of depression. The three main aims, 
outlined below, examined the key components of these models, (1) goal-directed 
activation, (2) positive reinforcement, and (3) punishment in one’s environment as 
potential mediators of the relationship between depressive symptoms and medication 
adherence. We assessed adherence to HAART as well as adherence to other daily 
medications. The overall aim was to illustrate how specific behavioral patterns common 
in depression may explain the powerful relationship between depression and medication 
adherence in a high-risk sample of substance users living with HIV/AIDS. 
Primary Aims and Hypotheses 
 
(1) Aim 1: Test goal-directed activation as a mediator of the relationship between 
depressive symptoms and medication adherence.  
a. Hypothesis 1: Goal-directed activation will mediate a negative relationship 
between depressive symptoms and medication adherence (see Figure i for 
directionality across all aims). 
(2) Aim 2: Test positive reinforcement in one’s environment as a mediator of the 
relationship between depressive symptoms and medication adherence.  
a. Hypothesis 2: Positive reinforcement in one’s environment will mediate a 
negative relationship between depressive symptoms and medication 
adherence.  
(3) Aim 3: Test punishment in one’s environment as a mediator of the relationship 
between depressive symptoms and medication adherence.  
a. Hypothesis 3: Punishment in one’s environment will mediate a negative 





Exploratory Aim  
 
(1) Exploratory Aim 1: Consider the potential mediators together to test whether the 
mediating effects are limited to a single variable or each provides incremental 
prediction. (see Figure i for a conceptual model of all study aims).  
Chapter 2: Method 
The current study tested the relationships between depressive symptoms, 
depression-related behavioral patterns, and medication adherence among substance users 
living with HIV/AIDS. Behavioral variables were derived from longstanding behavioral 
theories of depression (Lewinsohn, 1974; Ferster, 1973) that hold particular relevance to 
medication adherence. The main components of these models include (1) goal-directed 
activation, (2) positive reinforcement in one’s environment, and (3) punishment in one’s 
environment, each of which was hypothesized to be significantly correlated with 
adherence. Next, we aimed to examine these variables as potential mediators of the 
relationship between depressive symptoms and medication adherence and to assess 
whether these variables independently or together mediated the relationship between 
depressive symptoms and medication adherence.  
Medication adherence was assessed for HAART specifically as well as other daily 
medications prescribed (psychotropic medications, cardiovascular medications, diabetes 
medications, anticonvulsants, and hormones). We used two methods to assess both 
adherence to HAART and adherence to other forms of medication. For “HAART 
adherence” specifically, we examined: (1) Self-reported ratio of doses missed over the 





on HAART (n = 47). For “all medication adherence,” we examined: (1) Self-reported 
ratio of doses missed over the past four days, and (2) Frequency of reasons endorsed for 
medication nonadherence in the total sample (n = 73). Each measure of adherence was 
considered separately as the main outcome across analyses.  
Recruitment 
 
 Participants for this study were first recruited as part of an ongoing randomized 
control trial (RCT) evaluating ACT HEALTHY (Daughters et al., 2010), an integrated 
behavioral activation based intervention (Daughters et al., 2008; Magidson et al., 2011) 
combined with Life-Steps (Safren et al., 1999), examining effects on depression, 
substance use, and medication adherence. The current study was drawn from the baseline 
data of this trial, conducted prior to randomization to treatment condition and the start of 
the study intervention. Recruitment for this trial ended in September of 2011, and to meet 
the sample size requirements of the current study, 15 additional participants were 
recruited (baseline assessment only) using an addendum to the larger trial protocol. All 
procedures for the baseline assessment remained the same.  
 All participants were recruited from the Salvation Army Harbor Light Substance 
Abuse Treatment Center in Northeast Washington, D.C. The center requires complete 
abstinence from drugs and alcohol, with the exception of caffeine and nicotine; regular 
drug testing is provided and any use is grounds for dismissal from the center. When 
needed, detoxification from an outside source is required prior to entry into the center. 
Aside from scheduled activities (e.g., group retreats, physician visits), residents are not 





often meet criteria for a dual diagnosis, treatment for mental health problems other than 
substance use is typically not available, and the treatment center does not have a 
psychiatrist on staff. Patients with psychiatric problems receive substance abuse 
treatment at this center but off-site health centers are utilized to provide pharmacological 
treatment (~25% of patients).  
 Participants had to meet the following inclusion criteria: 1) minimum of 18 years 
of age; 2) complete detoxification as needed prior to entry into the center and/or be drug 
free for at least one week prior to study participation; and 3) diagnosed with HIV/AIDS. 
Patients were excluded if they did not meet all inclusion criteria or if they met diagnostic 
criteria for a current psychotic disorder (as measured by the SCID-IV; First & Gibbon, 
2004). For the current study, participants were excluded from all analyses if they were 
not prescribed any daily medication, which was necessary to assess medication 
adherence. 
 The importance of protecting participant confidentiality greatly influenced our 
recruitment strategy. Specifically, the administrative office of the treatment center was 
aware of patients’ HIV status, and they approached HIV positive residents and asked if 
they were interested in hearing about a research study conducted by our team, which was 
independent of their status and treatment at Harbor Light. We were extremely sensitive to 
the potential for coercion. We provided no advantage to the administrative staff in 
referring clients to us. Further, staff members were informed that clients often do not 
meet inclusion criteria, so they were unable to determine if a referred patient not 
participating declined participation or was ineligible. It is notable that we regularly 





automatically labeled as “HIV positive” if others saw them spending time with our 
research team. Further, patients who were not HIV positive were not informed that an 
HIV-specific study was being conducted.  
If individuals were interested in participating, they were invited for an initial 
interview and screening assessment to confirm their eligibility. The screening assessment 
included the Structured Clinical Interview for the DSM-IV (SCID-IV; First & Gibbon, 
2004) and a brief medical questionnaire. Individuals who did not meet criteria or who 
were ineligible based on data obtained during interviews were excluded from the study. 
Participants who met criteria were provided written informed consent and participated in 
the baseline assessment session, which took place during individuals’ first two weeks at 
the substance abuse treatment center. As our team has been doing at Harbor Light (for the 
past 9 years), assessment sessions occurred during the patients’ free time on either 
Tuesday evening or Friday afternoon so as not to interfere with treatment. All assessment 
measures proposed in the current study were included in an existing protocol approved by 
the University of Maryland Institutional Review Board (IRB). To reduce attrition, 
monetary incentives were used. Participants were compensated 20$ in gift cards for 
completing the assessment.  
Participants  
 
Eighty participants met all inclusion criteria for the current study. Three declined 
participation, and four were excluded from current analyses because they were not 
prescribed any type of daily medication regimen, which was not included in the exclusion 





study. Of the final sample (n = 73), 94.5% of the sample was African American, 71.2% 
heterosexual, 50.7% female, and the mean age was 45.0 (S.D. = 7.8). Regarding 
psychopathology, the most prevalent disorders in the sample included current major 
depressive disorder (MDD; 17.8%), lifetime MDD (45.2%), bipolar I disorder (15.1%), 
lifetime posttraumatic stress disorder (PTSD; 19.2%), past year crack/cocaine 
dependence (54.8%), past year alcohol dependence (32.9%), past year opioid dependence 
(24.7%), and antisocial personality disorder (ASPD; 27.8%). The remaining disorders 
assessed (all anxiety disorders, other substance use disorders, and borderline personality 
disorder) were of less than 15% prevalence in the current sample. In total, 64.4% (n = 47) 
of the current sample was prescribed HAART, and 35.6% (n = 26) was not prescribed 
HAART (based on self-report and medical records). Tables i and ii provide more 
information on demographics, Axis I and II psychopathology, health status, and health-
care related factors for the total sample and broken down by HAART use.  
Assessment Measures 
 
 Measures were organized into six domains: (a) demographics, psychopathology, 
and medical history to determine eligibility and considered as covariates in analyses; (b) 
depressive symptoms, both self-report and clinician-rated, included as separate 
independent variables (IVs) across all Aims; (c) measures of goal-directed activation and 
positive reinforcement/punishment in one’s environment, included as the potential 
mediators across all Aims; (d) medication adherence (for both HAART and other daily 
medications) assessed using self-report methods and biological measurement of viral load 
for individuals on HAART, which were the primary outcome measures across all Aims; 





a) Demographics, psychopathology, medical history  
Demographics form assessed age, race/ethnicity, education level, marital status, 
employment status, and annual household income.  
The Structured Clinical Interview for the DSM-IV (SCID-IV; First & Gibbon, 
2004) was used to assess lifetime and current DSM-IV Axis-I psychopathology and select 
Axis II disorders including borderline personality disorder (BPD) and antisocial 
personality disorder (ASPD). The SCID was conducted by trained interviewers (graduate 
students and post-baccalaureate research assistants) during participants’ first week at the 
substance abuse treatment center as part of a screening for eligibility. 
The Medical Questionnaire was a brief questionnaire administered at the SCID 
interview that assessed history of chronic medical conditions (including HIV) and daily 
medication use. This information was verified with Center records and used to determine 
study eligibility.   
b) Depressive symptoms 
The Beck Depression Inventory (BDI-II; Beck, Steer, Ball, & Ranieri, 1996)
 
is a 
21-item self-report measure of depressive symptoms. Sample items include “sadness” 
and “loss of pleasure.” Higher scores suggest increased depression severity. The 
instrument has excellent internal consistency (α =.92) with depressed younger and older 
adults (Beck et al., 1996; Nezu, Ronan, Meadows, & McClure, 2000). The BDI-II was 





The Hamilton Depression Rating Scale – 7 item version (HAMD-7; Maier & 
Phillip, 1985) is a clinician-rated measure of severity of depressive symptoms. Clinicians 
rate each of the 7 items on a scale of 0-4 with higher scores indicating increased 
depression severity. Sample items include “Have you been feeling down or depressed this 
past week? How often have you felt this way, and for how long?” and “In the past week, 
have you felt guilty about something you’ve done, or that you’ve let others down?” 
Previous research has shown that the measure has strong internal consistency (α =.84) 
and excellent convergent validity with the Montgomery-Asberg Depression Rating Scale 
(MADRS) (r = .90; McIntyre et al., 2005). The HAMD was assessed as a measure of 
clinician-rated depressive symptoms as an IV across all aims.  
Given that discrepant scores have often been noted when correlating self-report 
and clinician-rated assessment more generally (i.e., using the HAMD and BDI; Bailey & 
Coppen, 1976; Enns, Larson & Cox, 2000; Sayer et al., 1993) and among HIV positive 
substance users specifically (Gonzalez et al., 2011b), we examined each measure of 
depressive symptoms in separate analyses and treated them as separate IVs for all Aims.  
c) Goal-directed activation and positive reinforcement/punishment in one’s 
environment 
Goal directed activation: The Behavioral Activation for Depression Scale (BADS; 
Kanter, Mulick, Busch, Berlin, & Martell, 2007) measures the frequency of activation, 
escape, and avoidance behaviors outlined in behavioral theories of depression. The 25-
item measure includes a four factor scale (Activation, Avoidance/Rumination, 





activation” and completion of scheduled activities (for example, “I engaged in a wide and 
diverse array of activities” and “I did something that was hard to do but it was worth it”). 
The “Avoidance/Rumination” subscale measures avoidance of negative aversive states 
and engaging in rumination rather than active problem solving (e.g., “I did things to 
avoid feeling sadness or other painful emotions,” “I tried not to think about certain 
things”). The “Work/school impairment” subscale represents inactivity and passivity 
regarding work and school responsibilities (e.g., “I took time off of work, or other 
responsibilities simply because I was too tired or didn't feel like going in,”) and “Social 
impairment” reflects inactivity and passivity regarding social activities (e.g., and “I was 
withdrawn and quiet, even around people I know well”). Higher scores indicate greater 
activation and lower impairment/avoidance across all subscales. The BADS has been 
demonstrated to have strong internal consistency (α = .92)
 
and good test-retest reliability 
(r = .74) in depressed and non-depressed samples (Kanter et al., 2007; Kanter, Rusch, 
Busch, & Sedivy, 2009). In the current sample, internal consistency for the total score 
and four subscales ranged from acceptable to good (Activation: α = .80; 
Avoidance/Rumination: α = .86; Work/School Impairment: α = .79; Social Impairment: α 
= .72; BADS total score: α = .85). The BADS was used to test the mediating role of goal-
directed activation. 
Positive reinforcement/punishment in one’s environment: The Reward Probability 
Index (RPI; Carvalho et al., 2011) measures the degree of positive reinforcement and 
punishment in one’s environment and was developed specifically in line with 
Lewinsohn’s model of depression. The RPI has 20 items and a two-facture structure, 





Probability subscale consists of 11 items related to the number of potential reinforcers 
and an individual’s ability to obtain reinforcement through instrumental behaviors. 
Example items in this subscale include “It is easy to find good ways to spend my time” 
and “I have the abilities to obtain pleasure in life.” Higher scores indicate greater 
probability of reward in the environment. The Environmental Suppressors subscale 
includes 9 items that assess availability of potential reinforcers and the presence of 
aversive stimuli in the environment. Example items include “I have had many unpleasant 
experiences” and “It seems like bad things always happen to me.” Items in this subscale 
are reverse scored, and higher scores on this subscale indicate lower levels of punishment 
in one’s environment. The RPI has been demonstrated to have strong internal consistency 
(α = .90), test-retest reliability (r = .69), convergent validity (with strong correlations 
between the RPI and measures of activity, avoidance, reinforcement, and depression [r = 
.65 to .81]), and discriminant validity (with smaller correlations between the RPI and 
measures of social support and somatic anxiety [r = -.29 to -.40]). In the current sample, 
internal consistency for the total score and the two subscales ranged from acceptable to 
good (Environmental Suppressors: α = .70; Reward Probability: α = .86; RPI Total Score: 
α = .79). The RPI Reward Probability subscale was used to test the mediating role of 
positive reinforcement in one’s environment, and the RPI Environmental Suppressors 
subscale was used to test the mediating role of punishment.  
d) Medication Adherence: All medications and HAART adherence specifically 
We assessed both adherence to all daily medication regimens, including HAART, 





anticonvulsants, and hormones in the total sample (n = 73), as well as adherence to 
HAART specifically only among participants taking HAART (n = 47).  
Self-reported medication adherence: We used a widely utilized self-report 
measure of medication adherence, the ACTG Adherence to Antiretroviral Medication 
Questionnaire (Chesney et al., 2000a), to measure medication adherence for all 
medications. Participants began by reading a set of directions that highlight how difficult 
it is for many patients to adhere to various medication regimens, providing support for 
truthful answers that acknowledge both adherent as well as nonadherent behavior. Next, 
participants provided the following information for each of their medications (HAART 
and all non-HIV medications): (1) name of drug; (2) prescribed doses per day; (3) 
prescribed number of pills per dose; and (4) any special directions, such as ‘with food’, 
‘on an empty stomach’ or ‘with plenty of fluids.’  
Four-day adherence ratios (for all medications and HAART specifically): 
Participants were next asked about the pills that they took for each of the last four days, 
including the name of each medication and how many pills they had missed that day.  
This information was used to create two separate sets of ratios of doses missed vs. doses 
prescribed over the past four days for 1) HAART specifically; and 2) all daily 
medications.  
Frequency of reasons endorsed for nonadherence: In the last section of the ACTG 
(Chesney et al., 2000a), participants were presented a list of 14 reasons why people may 
ever miss taking their medications (e.g. being away from home, busy with other things, 





because you…” for each reason. Participants rate responses on a four-point scale (never, 
rarely, sometimes, often) to indicate the frequency of nonadherence due to each of the 14 
reasons. The responses were summed to create a total score of frequency of reasons 
endorsed for medication nonadherence, with higher scores indicating greater frequency of 
reasons endorsed for nonadherence. There is no specified time frame for this part of the 
ACTG.  
Querying for reasons for nonadherence has been recommended as a way to 
minimize potential biases of self-report when assessing adherence, including inaccurate 
recall and social desirability, as is wording questions in a way that assumes nonadherence 
(Simoni et al., 2006). This method has been used in other studies as a main adherence 
outcome as a means to capture a wider time frame for nonadherence beyond the past four 
days and minimize potential inaccuracies of self-reported adherence (O’Cleirigh, Ironson, 
& Smits, 2007; DiIorio et al., 2009). We did not distinguish between HAART and other 
types of medications when assessing reasons for nonadherence and thus only examined 
the frequency of reasons endorsed for nonadherence for all medications (as opposed to 
examining reasons endorsed for nonadherence of HAART specifically). In the current 
sample, internal consistency for the nonadherence reasons subscale was excellent α = .90. 
Biological indicator of HAART adherence: We also assessed a common 
biological indicator of medication adherence, Viral Load, which is a measure of the 
amount of HIV virus in the bloodstream and represents a more objective measure of 
HAART adherence for individuals on HAART. Viral load has repeatedly demonstrated a 
significant correlation with HAART adherence (Arnsten et al., 2001; Glass et al., 2006; 





associated with an undetectable amount of virus in the blood stream (i.e., <50 
copies/mL). Viral load has been selected most commonly as a clinical criterion to reflect 
adherence, as it is considered a more proximal indicator of adherence (i.e., compared to 
CD4 count; Safren et al., 2009; Simoni et al., 2006). Specifically, we obtained consent 
from all participants to receive copies of their blood work information from their medical 
provider (within -60/+30 days from assessment). When blood work was not scheduled 
during this time, participants were requested to get it taken (which was clearly outlined in 
the patient consent form). In the current sample, participants on average had received 
blood work 9.57 days before the assessment (S.D. = 30.35 days). Given the high skew of 
viral load values in the literature and in the current sample (skewness = 4.08, SE = 0.29), 
viral load was log10 transformed for all analyses, which is the most common approach to 
analyzing viral load data in the field. 
In sum, in measuring medication adherence for the current study, we used two 
measures of “all daily medication adherence”: (1) Ratio of doses missed over the past 
four days; and (2) Frequency of reasons endorsed for nonadherence score; and two 
measures of “HAART adherence” specifically: (1) Self-report (ratio of doses missed over 
the past four days); and (2) Clinical indicator of adherence (viral load), which is in line 
with clinical recommendations in the field (e.g., Miller & Hays, 2000; Reynolds, 2004).  
We treated each measure of medication adherence as a separate dependent variable (DV) 
across all Aims.  





Self-reported health status was assessed using the Quality of Life: SF-36 (Ware, 
Kosinski, & Keller, 1994), which is a self-report measure of overall physical and mental 
health functioning. The SF-36 examines quality of life in multiple dimensions: general 
health, physical functioning, role-physical, bodily pain, vitality, social functioning, role-
emotional, mental health, and reported health transitions, and two summary scales can be 
computed: a physical health and mental health status total score. The measure has been 
widely used and validated across numerous health settings and patient populations 
(McHorney, Ware, & Raczek, 1993; McHorney, Ware, Lu, & Sherbourne, 1994; Ware & 
Gandek, 1998). Biological health status was assessed using CD4 count, a measure of 
immune system functioning and disease progression. This was obtained from 
participants’ medical records of the most recent blood work appointment (-60/+30 days 
from current assessment) in line with the procedure stated above for obtaining viral load. 
Participants also self-reported Years since HIV Diagnosis and basic health care-related 
characteristics, such as whether they reported having a primary care physician (PCP) and 
a health insurance plan. All health status measures were considered as potential 
covariates across all Aims. 






Table 1. List of assessment measures by domain at each study assessment session. 
Assessment Screening Assessment 
Demographics and Psychopathology 
Demographics Form  X 
SCID-IV X  
Medical Questionnaire  X  
Depressive Symptoms 
BDI-II   X 
HAMD    X 
Activation, Reinforcement/Punishment 
BADS  X 
RPI  X 
Medication Adherence (All medications)  
Ratio of doses missed in past 4 days  X 
Frequency of reasons endorsed for 
nonadherence  
 X 
HAART adherence  
Ratio of doses missed in past 4 days   X 





CD4 Count    X 






Data Analytic Plan Overview 
 
Sample size considerations 
We based our sample size needs on effects published in studies related to 
depression, environmental/activation-related variables, and medication adherence that 
tested closely related variables, as well as effects observed in our pilot data in this area. 
Regarding relationships between the independent variable (depressive symptoms) and 
mediators (goal-directed activation, positive reinforcement/punishment in one’s 
environment), published reports have demonstrated medium to large effect sizes for both 
the relationship between goal-directed activation and depressive symptoms (r = -.72; 
Kanter et al., 2009) and the relationship between positive reinforcement/punishment in 
one’s environment and depressive symptoms (r = -.74; Carvalho et al., 2011). Regarding 
the relationship between the mediators (goal-directed activation and positive 
reinforcement/punishment in one’s environment) and the dependent variable (medication 
adherence), effect sizes were drawn from related studies examining the relationship 
between daily activity engagement and medication adherence, as well as pilot data in this 
area (Daughters et al., 2010), all pointing to medium to large effect sizes (r = -0.44 to -
0.63) (Wagner & Ryan, 2004). Regarding the relationship between the IV, depressive 
symptoms, and the DV, medication adherence, recent work examining depressive 
symptom severity and medication nonadherence in a sample of HIV positive substance 
users observed a large effect size (Cohen’s d = 0.98; Gonzalez et al., 2011b). According 
to Fritz & MacKinnon (2007), the necessary sample size for partial mediation to have a 





medium to large effect sizes (0.39 to 0.59 for the alpha and beta paths) using bias-
corrected bootstrapping. Thus, we proposed 75 participants to test for mediation and to 
plan for refusal and dropouts.  
Statistical analyses overview 
 There were numerous steps in our data analytic plan. All data first were double-
entered, compared, cleaned, and verified for accuracy. For all continuous variables, we 
examined distributional properties and checked for outliers by examining skewness and 
kurtosis. This was of particular concern for the dependent variables (viral load, past four 
day adherence ratios), and our approach for handling the high skew of these variables is 
detailed below.  
We next identified potential covariates for analyses by examining the relationship 
between the set of theoretically driven covariates identified a priori, including 
demographic and health status-related variables, and the dependent variables. Given the 
high skew of viral load values in the literature and in the current sample (skewness = 
4.08, SE = 0.29), viral load was log10 transformed for all analyses, which is the most 
common approach to analyzing viral load data in the field. We also examined viral load 
categorically among individuals on HAART, comparing individuals based on detectable 
viral load status (VL ≤ or > 50). Given the main focus on medication adherence in the 
current study and that not all participants were prescribed HAART, we also compared 
individuals using HAART vs. not using HAART to assess any group differences in these 
same covariates to be overly conservative when identifying potential covariates. Finally, 





15 participants were recruited to meet the sample size needs for the current study), we 
also compared these 15 individuals to the remainder of the sample recruited from the 
larger trial on all key variables. 
 As the first step to plan for mediation analyses, we conducted two separate 
correlation matrices to identify candidate mediators. We first examined the correlations 
between both measures of the IV (HAMD, BDI), potential mediators (subscales of the 
BADS and RPI), and frequency of reasons endorsed for all medication nonadherence for 
the total sample (n = 73). We then conducted a correlation matrix examining the 
relationship between the IVs, potential mediators, and viral load only among individuals 
on HAART (n = 47). A variable was considered as a potential mediator in subsequent 
analyses if there was a significant association between one of the IVs and the potential 
mediator (a path), and the mediator(s) and the DV (b path). There has been some debate 
in the literature as to whether the direct relationship between the IV and DV (c path) 
needs to be significant for mediation; in order to identify any potential indirect effects 
that may not rely on the direct effect of the IV on the DV, we also considered potential 
indirect effects even if the IV and DV were not significantly related, as recommended by 
Hayes (2009).  
 We next conducted two sets of analyses to test for mediation. We first ran a series 
of linear regression analyses to test whether the four criteria set by Baron & Kenny 
(1986) were met, if there was  (1) a significant direct effect of the IV on the DV; (2) a 
significant effect of the IV on the potential mediator; (3) a significant effect of the 





the mediator was no longer significant but the effect of the mediator remained significant 
in the model.  
 Second, we also utilized non-parametric bootstrapping to test for significance of 
the indirect effect, which is recommended for small samples, because there are no 
assumptions about the shape of the sampling distribution of the indirect effect (Preacher 
& Hayes, 2004). Bootstrapping is based on resampling with replacement which is done 
many times (e.g., 5,000 times) to generate an empirical approximation of the sampling 
distribution of the indirect effect (Hayes, 2009). In these analyses, the indirect effects are 
significant if the 95% bias-corrected or percentile-based confidence intervals (CIs) for the 
indirect effect do not include 0 (Preacher & Hayes, 2004; Preacher et al., 2007). Given 
that the mean of the bootstrapping distribution will not precisely equal the indirect effect, 
both endpoints of the CIs are typically corrected for bias. However, there has been some 
controversy regarding bias-corrected bootstrapping tests being too liberal (Fritz, Taylor, 
& MacKinnon, 2012). As such, we utilized both the bias-corrected and percentile-based 
95% CIs to interpret the significance of indirect effects and examined whether 0 was 
included in either CI. Given that the current study was cross-sectional, we also ran the 
proposed mediation models switching the mediator and DVs to demonstrate that the DV 
was not also mediating the relationship between the IV and proposed mediators (Preacher 
& Hayes, 2004). Given the potential bi-directionality of this relationship (i.e., 
improvements in adherence resulting in improvements in depressive symptoms), we also 






Chapter 3: Results 
Overview of Medication Adherence in Current Sample 
 
As indicated above, 64.4% (n = 47) of the current sample was prescribed HAART 
(based on self-report and medical records). Participants on HAART were taking an 
average of 3.22 HIV medications per day (S.D. = 1.84). In the total sample, participants 
were taking an average of 5.84 medications per day (S.D. = 3.50). 41.7% of the sample 
was taking cardiovascular drugs, 40.3% antidepressant medication, 16.7% anticonvulsant 
medication, 13.9% diabetes medication, and 4.2% were taking daily hormones. Of 
individuals on HAART, 97.8% were prescribed an NRTI, 58.7% a PI, 26.1% integrase 
inhibitors, 2.2% entry fusion inhibitors, 2.2% NNRTIs, and 21.7% a combination pill of 
NRTI and NNRTIs (i.e., Atripla).  
Rates of medication adherence 
We assessed adherence to all daily medication regimens, including HAART, 
psychotropic medications, cardiovascular medications, diabetes medications, 
anticonvulsants, and hormones, as well as adherence to HAART specifically only for 
patients that were on HAART (n = 47). We calculated adherence ratios (i.e., doses taken 
vs. doses prescribed for each participant) for both HAART specifically and all daily 
medications for the total sample. For HAART specifically, mean adherence rates ranged 
from 94.57% to 100% in the past four days for HAART; HAART adherence rates were 
100% yesterday, 94.57% two days ago, 97.83% three days ago, and 97.83% four days 





the past four days; all daily medication adherence rates were 97.33% yesterday, 94.93% 
two days ago, 96.51% three days ago, and 97.74% four days ago. 
There was little variability in rates of nonadherence over the past four days, and 
more specifically a ceiling in rates of nonadherence was present. All adherence ratios 
were highly skewed (skewness statistics < -4.5 for all ratios), which was not improved 
following transformations. As such, we could not utilize these ratios as main outcome 
variables for adherence. Instead, we focused on the two other main adherence outcome 
variables assessed – viral load (for individuals on HAART) and frequency of reasons 
endorsed for nonadherence for all medications – that captured a greater time frame of 
nonadherence and also did not ask for patients to report on missed doses directly, which 
previous research has noted is susceptible to inflated adherence rates (Kalichman et al., 
2009; Simoni et al., 2006).  
Frequency of reasons endorsed for nonadherence was in the normal range for 
skew and kurtosis and was not transformed. Responses ranged from 0 to 36, and the 
mean in the current sample was 11.97 (S.D. = 9.42). Mean log10 viral load for the total 
sample was 2.40 (S.D. = 1.08). For individuals on HAART, mean log10 viral load was 
1.98 (S.D. = .83).   
Identifying potential covariates 
Covariates Related to DV 
As indicated above, we first identified any potential covariates that were related to 
either of the DVs (frequency of reasons endorsed for nonadherence or viral load). The set 





indicating their relevance to medication adherence and viral load, including a range of 
demographic and health status-related variables. None of these factors were significantly 
related to frequency of reasons for medication nonadherence (all ps > .05). CD4 count 
was related to log10viral load and was identified as a covariate for all subsequent 
analyses that used viral load as the DV (see Table iv for all relationships between 
potential covariates and both DVs).  
Covariates that Differentiate Individuals on HAART vs. Not 
Given the main focus on medication adherence in the current study and that not 
all participants were prescribed HAART, we also compared individuals taking HAART 
vs. not taking HAART to assess any group differences in demographics, 
psychopathology, health status, or health-related characteristics that would be important 
to control for in analyses (see Tables i and ii). We also examined group differences in 
levels of depressive symptoms (the IV), activation, positive reinforcement, and 
punishment (the potential mediators), and medication adherence (the DV), comparing 
individuals using HAART vs. not using HAART to ensure equivalence across groups for 
these key variables (see Table iii). As indicated in these tables, the only significant 
difference (at p < .05) across groups was in viral load; specifically, individuals on 
HAART had significantly lower viral load compared to individuals not on HAART (t(63) 
= -6.56, p < .0001). This difference in viral load was expected as a direct result of 
HAART use. Given that we are examining viral load as an indicator of HAART 
adherence only among individuals on HAART, this would not impact the analyses and 
was not included as a covariate. We also compared the additional 15 participants that 





larger trial on all key variables. There were no significant differences across groups on 
any potential covariate or other key variables for analyses (all ps > .15). 
Identifying Potential Mediators  
 
  As the first step to plan for mediation analyses, we next conducted two 
correlation matrices to identify candidate mediators. We first examined the correlations 
between both measures of the IV (HAMD, BDI), potential mediators (BADS, RPI), and 
the DV (frequency of reasons endorsed for nonadherence to all medications) in the total 
sample (n = 73). We then conducted a correlation matrix examining the relationship 
between the IVs, potential mediators, and viral load as the DV only among individuals on 
HAART (n = 47). As indicated above, there was insufficient variation in past four day 
nonadherence for all medications and HAART specifically to include these as DVs. See 
tables v and vi for the results of both correlation matrices.  
 From the results of the correlation matrices (tables v and vi), a variable was 
considered as a potential mediator if there was a significant association between one of 
the IVs and the potential mediator (a path), and the mediator(s) and the DV (b path), 
which included either 1) frequency of reasons endorsed for medication nonadherence for 
the total sample; or 2) viral load for individuals on HAART.  
 As indicated in table v, the only variables significantly related to frequency of 
reasons endorsed for medication nonadherence were HAMD and punishment (the RPI 
environmental suppressors subscale [lower scores = greater punishment], with greater 
depressive symptoms (r = .26, p = .03) and higher levels of punishment (r = -.39, p = 





HAMD was also significantly related to frequency of reasons endorsed for medication 
nonadherence (r = .26, p = .03).  
 As indicated in table vi, neither depressive symptoms nor any potential mediators 
were significantly related to viral load. We also examined viral load categorically among 
individuals on HAART, comparing individuals based on detectable viral load status (VL 
≤ 50). We tested any differences for all key study variables (IVs and potential mediators), 
and there were no significant differences between individuals with a detectable viral load 
vs. undetectable at p < .05 (see Table viii).  
 Based on the results of the correlation matrices (tables v and vi), the only 
potential indirect effect to test in further analyses was the role of punishment 
(environmental suppressors subscale of the RPI) in the relationship between clinician-
rated depressive symptoms and frequency of reasons endorsed for medication 
nonadherence for all participants. Specifically, the a and b paths were statistically 
significant: clinician-rated depressive symptoms (HAMD) were significantly related to 
punishment (r = -.26, p = .03), and punishment was significantly related to total 
medication nonadherence (frequency of reasons endorsed; r = .39, p = .001). 
Additionally, although not necessarily a requirement for mediation (Hayes, 2009), the c 
path was also significant: HAMD was significantly related to frequency of reasons 
endorsed for nonadherence (r = .26, p = .03). Thus, we chose to test punishment as a 
potential mediator of the relationship between HAMD and frequency of reasons endorsed 
for medication nonadherence.  






 We tested the mediating role of punishment in the relationship between 
depressive symptoms and frequency of reasons endorsed for all medication nonadherence 
(aligning with originally proposed Aim 3) using two approaches. We first ran a series of 
linear regression analyses without covariates to test whether the four criteria set by Baron 
& Kenny (1986) were met. There was (1) a significant direct effect of the IV (HAMD) on 
the DV (frequency of reasons endorsed for medication nonadherence) (B = .72, t(61) = 
2.05, p < .05); (2) a significant effect of the IV(HAMD) on the potential mediator 
(punishment) (B = -.36, t(68) = -2.19, p < .05); (3) a significant effect of the mediator 
(punishment) on the DV (frequency of reasons endorsed for medication nonadherence) (B 
= -.81, t(64) = -3.32, p < .001); and (4) the effect of the IV (HAMD) on the DV 
(frequency of reasons endorsed for medication nonadherence) after controlling for the 
mediator (punishment) was no longer significant (B = -.50, t(61) = 1.46, p = .15), but the 
effect of the mediator (punishment) remained significant in the model (B = -.76, t(61) = -
.2.89, p < .01).  See Figure ii for a depiction of these relationships.  
 We also utilized non-parametric bootstrapping to test for significance of the 
indirect effect, which has been demonstrated to be a valid and powerful method for 
testing indirect effects (MacKinnon et al., 2004; Shrout & Bolger, 2002; Williams & 
MacKinnon, 2008). It is recommended for small samples because there are no 
assumptions about the shape of the sampling distribution of the indirect effect, unlike the 
Sobel test that assumes the sampling distribution of the indirect effect is normal (Preacher 
& Hayes, 2004). In these analyses, the indirect effects are significant if the 95% bias-





include 0 (Preacher & Hayes, 2004). We utilized both bias-corrected and percentile-based 
CIs to interpret the significance of indirect effects. 
 The analyses were based upon 5,000 bootstrapped samples (recommended by 
Hayes, 2009), and we used the INDIRECT SPSS Macro developed by Preacher & Hayes 
(2008). See table vii for the bias-corrected and percentile-based CIs and point estimate 
for the indirect effect. Because zero was not included in either of the 95% CIs, the 
indirect effect was determined to be significantly different from zero at p < .05 (two-
tailed). Specifically, individuals who demonstrated higher levels of clinician-rated 
depressive symptoms were more likely to perceive punishment in their environment, and 
through higher levels of punishment, were more likely to endorse a greater frequency of 
reasons for medication nonadherence (see table vii).
2
 
 Finally, given that the current study was cross-sectional, we also ran the proposed 
mediation models switching the mediator and DV to demonstrate that the DV was not 
also mediating the relationship between the IV and proposed mediators (Preacher & 
Hayes, 2004). We tested this using 5,000 bootstrapped samples using the same Macro 
(Preacher & Hayes, 2008). Results indicated there was not a significant indirect effect of 
the DV according to both the percentile-based and bias-corrected 95% CIs [I.E. = -.11, 
S.E. = .09; percentile-based 95% CI: LL = -.31, UL = .03; bias-corrected LL = -.37, UL = 
.01]. In sum, because zero was included in both the percentile-based and bias-corrected 
95% CI, this suggested that the DV (frequency of reasons endorsed for nonadherence) did 
not mediate the relationship between depression and punishment.   
                                                          
2
 We conducted these analyses with and without controlling for HAART status, and the results did not 
differ (in both analyses, the percentile-based and bias-corrected CIs did not include 0). Controlling for 
HAART status, the point estimate of the indirect effect based on 5,000 bootstrapped samples = .23, bias = 





 Given the potential bi-directionality of this relationship (i.e., improvements in 
adherence resulting in improvements in depressive symptoms), we also ran the proposed 
mediation models switching the IV and DV to demonstrate that punishment was not also 
mediating the relationship between nonadherence as the IV and depressive symptoms as 
the DV. We again tested this using the same procedure stated above (Preacher & Hayes, 
2008). Results indicated that there was not a significant indirect effect of punishment 
when the IV and DV were switched according to both the percentile-based and bias-
corrected 95% CIs [I.E. = .02, S.E. = .02; percentile-based 95% CI: LL = -.01, UL = .07; 
bias-corrected LL = -.01, UL = .08].  
Exploratory Aim  
 As an exploratory aim we initially wanted to consider multiple mediators together 
in the same model; however, as indicated above, no other potential variables besides 
punishment were eligible for inclusion in a larger multiple mediator model based on their 
relationships with either IV or DV. As such, we could not test the exploratory aim. 
Chapter 4: Discussion 
 The current study sought to improve our understanding of potential mechanisms 
underlying the impact of depression on medication nonadherence drawing from early 
behavioral models of depression (Ferster, 1973; Lewinsohn, 1974). We aimed to test the 
key components of these models, (1) goal-directed activation, (2) positive reinforcement, 
and (3) punishment in one’s environment as potential mediators of the relationship 
between depressive symptoms and medication adherence. Given the significant focus on 





as chronic health conditions more generally (DiMatteo et al., 2000), yet scarce research 
testing potential explanatory mechanisms of this relationship, findings have important 
implications for informing our understanding of a potential mechanism by which 
depression may impact adherence. This is directly in line with numerous recent reviews 
that have pointed to the critical need for studies to test mediators of this relationship (e.g., 
Gonzalez et al., 2011a).  
 The current study recruited low-income, HIV positive substance users who are at 
high risk for poor HIV outcomes (i.e., resulting from HAART nonadherence or not being 
on HAART; Chander et al., 2009). Indeed, we found that a substantial portion of our 
sample recruited was not taking HAART (35.62%), further supporting the notion that this 
is a sample at extremely high risk for poor HIV outcomes. Given that a high proportion 
of the sample was not taking HAART, in addition to assessing HAART adherence, we 
also assessed adherence to other daily medication regimens (i.e., psychotropic 
medications, cardiovascular medications, diabetes medications, anticonvulsants, and 
hormones), which has been suggested to be a strong predictor of HAART adherence and 
may be particularly important for improving HIV outcomes in this population (Cruess et 
al., 2012; Wagner, 2003).  
 We assessed adherence using self-reported missed doses during the past four days 
(for all medications and HAART specifically), as well as two measures of adherence that 
capture a wider time window: frequency of reasons endorsed for nonadherence more 
generally and viral load. Rates of self-reported adherence in the past four days were 
extremely high, reaching almost 100%; this may reflect typical inflation of self-reported 





2009; Liu et al., 2001; Simoni et al., 2006) or actual high adherence rates common in the 
context of a controlled, substance abuse treatment setting (Hicks et al., 2007). In sum, the 
ceiling in rates of self-reported missed doses may be a reflection of either limitations of 
the assessment method, closely monitored medication schedules in a controlled setting, or 
the limited time window of four days. As an alternative, we utilized the two adherence 
measures that captured a greater time window (frequency of reasons endorsed for 
nonadherence and viral load).  
There was indeed greater variability in the other two main adherence outcome 
variables (frequency of reasons endorsed for missed doses of all medications and viral 
load). As indicated above, there was not a timeframe specified in the measure of reasons 
for nonadherence, and as such, even participants who did not miss doses in the past four 
days may have indicated reasons for nonadherence, for instance prior to coming to 
substance abuse treatment. Additionally, participants may have endorsed reasons for 
nonadherence even if they did not report missed doses given a greater tendency to 
minimize nonadherence when asked to report on missed doses directly (Kalichman et al., 
2009; Liu et al., 2001; Simoni et al., 2006). Regarding viral load, this clinical measure 
typically reflects adherence rates over the past approximate three months, and clearly 
given that it does not rely on patient self-report may have captured greater rates of 
nonadherence (Liu et al., 2001; Miller & Hays, 2000). Thus, to assess overall medication 
nonadherence we used the single DV of frequency of reasons endorsed for nonadherence, 
and for HAART adherence, we used viral load. The self-reported ratios of missed doses 
(for HAART and other medications) were removed from further analyses given the 





DVs separately, as well as two measures of depressive symptoms: self-reported (BDI) 
and clinician-rated (HAMD).  
Summary of Findings 
 
Adherence to all medications: frequency of reasons endorsed for nonadherence  
 Regarding frequency of reasons endorsed for nonadherence to all medications, 
only clinician-rated depressive symptoms were related to nonadherence, such that greater 
clinician-rated depressive symptoms were related to greater frequency of reasons reported 
for nonadherence. Self-reported depressive symptoms were unrelated to frequency of 
reasons endorsed for nonadherence (r = .12, p > .05). The only proposed mediator related 
to frequency of reasons for nonadherence was punishment, such that a greater degree of 
punishment in one’s environment was related to greater frequency of reported reasons for 
nonadherence. Both activation and reward derived from one’s environment were 
unrelated to frequency of reasons endorsed for nonadherence.  
 As such, we only tested punishment as the mediator of the relationship between 
clinician-rated depressive symptoms and adherence. Testing this relationship using a 
series of linear regression analyses as well as non-parametric bootstrapping, punishment 
mediated the relationship between clinician-rated depressive symptoms and 
nonadherence. Specifically, individuals who demonstrated higher levels of clinician-rated 
depressive symptoms were more likely to perceive punishment in their environment, and 
through higher levels of punishment, were more likely to endorse reasons for medication 
nonadherence. It was an unexpected finding that punishment would be more strongly 





symptoms, particularly given the high correlation amongst depression-related self-
reported measures typically. It will be important to replicate this finding and explore 
several possible reasons in future work, including the possibility that factors associated 
with experiencing punishment in one’s environment may reflect deficits in particular 
skills (e.g., social skills) that are more accurately assessed using clinician observation as 
opposed to self-report.  
Punishment mediating the relationship between clinician-rated depressive 
symptoms and frequency of reasons endorsed for nonadherence is in line with the 
theoretical framework of external locus of control of reinforcement, particularly as 
applied to health behavior (Wallston, Wallston, & DeVellis; 1978). This theoretical 
framework suggests that the degree to which individuals expect that a particular outcome 
is contingent on their own behavior or personal characteristics is strongly related to the 
likelihood of engaging in that behavior (Rotter, 1975). Individuals with an external locus 
of control perceive little control or agency over behavioral outcomes, and as such are 
much less likely to persist with behaviors that may be difficult in the short-term but may 
lead to more positive long-term consequences (Rotter, 1966). This notion of lacking 
control over one’s environment and feeling more subject to negative consequences 
despite behavioral efforts suggests that punishment and external locus of control are 
closely linked constructs. Indeed, laboratory evidence suggests that uncontrollability in 
an environment (i.e., in line with an external locus of control) is strongly associated with 
greater perceived punishment, and in turn lower rates of responsive behavior (Hiroto, 
1974). Individuals with an external locus of control are more likely to report punishing 





healthy behavior (Rotter, 1966; Wallston et al., 1978). Although pinpointing causality or 
directionality in the relationship between punishment and external locus of control may 
be difficult or nearly impossible—a history of punishing or aversive consequences may 
lead to perceptions of lack of control over one’s environment, or alternatively an external 
locus of control may contribute to greater perceptions of punishment—evidence does 
support a strong relationship and overlap between these constructs (Rotter, 1966; 1975).  
As applied to health behavior specifically, an external locus of control has been 
strongly implicated in depression, in particular in relation to symptoms of depression 
related to avolition (Benassi et al., 1988), substance use (Newcomb & Harlow, 1986), and 
persistence with self-care across numerous chronic conditions, such as diabetes (Schlenk 
& Hart, 1984), hypertension (Stanton, 1987), as well as HIV/AIDS (Aversa & Kimberlin, 
1996; Evans et al., 2000). Individuals with an external health locus of control are less 
likely to perceive direct benefits from healthy behavior, and rather are more likely to 
report aversive consequences as a result of attempting healthy behavior and a lack of 
control over managing their health condition (Wallston et al., 1978). Regarding HAART 
specifically, individuals with an external health locus of control may be less likely to 
perceive the benefits or rewards associated with HAART adherence (e.g., taking control 
over one’s health), and rather may be more likely to report negative consequences when 
attempting to adhere (e.g., perceived stigma, side effects, etc.; Aversa & Kimberlin, 
1996; Evans et al., 2000). In sum, individuals with an external locus of control are more 
likely to perceive a lack of control over their health and more likely to report aversive 





In line with the locus of control framework, the current findings indicate that 
punishment may be very relevant to individuals endorsing more frequent reasons for 
medication nonadherence, and that punishment may be more important in explaining the 
relationship between depression and barriers to medication adherence than the other two 
main components of early behavioral theories of depression—levels of activation and 
reward in one’s environment. Although it has been well-established that activation and 
reward in one’s environment are strongly related to depression, it may be that these 
constructs are not as strongly related to medication nonadherence. Alternatively, it may 
also reflect the setting in which the current study was conducted, a controlled 
environment with very little variability or flexibility regarding one’s schedule. There are 
also very few ways to obtain reinforcement from one’s environment in this controlled 
setting. Both of these characteristics may have made activation and reinforcement in 
one’s environment less relevant to medication adherence in the recruitment setting. It 
would be interesting in future work to recruit from a community setting or an outpatient 
center where individuals have greater control over their schedule and opportunities for 
obtaining reinforcement in a more natural environment. It may be that in a different 
setting with fewer restrictions on one’s activity level and activity options that levels of 
activation and reinforcement in one’s environment would be more strongly related to 
medication nonadherence. However, these interpretations are speculative and require 
further empirical attention.  
Adherence to HAART: Viral load findings  
 Regarding the relationships tested only among individuals on HAART (i.e., using 





were related to viral load. As such, no analyses were conducted to test mediators of the 
relationship between depressive symptoms and viral load. There are a few potential 
reasons why no variables assessed were related to viral load. These analyses were only 
conducted among individuals taking HAART in the current sample (n = 47) given that 
viral load is only an indicator of adherence among individuals on HAART. Doing so 
greatly reduced the sample size, and potentially meaningful relationships may not have 
been able to be detected in such a reduced sample size, as the necessary sample size to be 
sufficiently powered to detect mediation using bootstrapping with the current effect sizes 
is approximately 54 to 71 (Fritz & MacKinnon, 2007).  There also may not have been 
sufficient variability in our measure of viral load (even following transformation) to 
detect meaningful differences.  
 Finally, it has been suggested that clinician-rated measures of depression may be 
stronger predictors of adherence than self-reported depressive symptoms, particularly for 
objective measures of adherence such as viral load (Gonzalez et al., 2011b). In line with 
this evidence, we would have expected HAMD scores to be related to viral load, although 
as stated previously the small sample size may have reduced the likelihood of detecting 
this effect. HAMD was significantly associated with actual viral load count prior to 
transformation (r = .31, p = .04), but was non-significant following the log10 
transformation. Effect sizes indicate a small to moderate relationship between HAMD 
and log10viral load (r = .19; d = .35). Given previous evidence that clinician-rated 
measures may be stronger predictors of objective adherence measurement (Gonzalez et 





objective measurements of the proposed mediators as well (i.e., using real-time objective 
assessments of activation) when testing this model using viral load as the primary DV.  
Limitations 
 
Findings must be interpreted in light of important study limitations. First and 
foremost, the study design was cross-sectional, which limits our ability to infer causality. 
Although the majority of studies to date still do test mediation using a cross-sectional 
design, there have been important advantages noted of using a longitudinal design to test 
for mediation (Maxwell & Cole, 2007). This point is particularly important given 
potential bi-directionality of this relationship. It has been suggested that improved 
physical well-being (i.e., through greater rates of adherence) may also influence 
depressive symptoms (Kagee, 2012). Successful adherence may also induce feelings of 
mastery and accomplishment, which as a result may reduce depressive symptoms (in line 
with behavioral theories of depression; Ferster, 1973; Lewinsohn, 1974). Although bi-
directionality was not empirically supported in the current study (i.e., when we re-ran 
mediation analyses switching the IV and DV), it is indeed an important limitation of a 
cross-sectional design that must be noted. Given the preliminary stage of current work—
that this is the first attempt to identify behavioral mediators of the relationship between 
depression and adherence—as well as the difficult to track nature of this population, we 
did feel that a cross-sectional design was most appropriate at this stage; however, future 
efforts to replicate these findings in a larger trial should consider incorporating long-term 
follow ups.  
A second important limitation of the current study relates to the measurement of 





measure of adherence for all medications, not only viral load. Although difficult in a 
controlled environment with little privacy, the use of electronic pill caps (for HAART as 
well as other medications) would have been a potentially more accurate, objective 
measure of adherence. However, there have also been limitations noted regarding 
electronic pill caps, including only being able to measure adherence to a single pill, 
inability to assess whether a pill was actually taken (vs. the bottle being opened), as well 
as noted patient burden of electronic pill caps (Liu et al., 2001). Lastly, electronic pill cap 
technology is very expensive and perhaps not appropriate at this stage of research and for 
the scope of this project. However, other potentially more objective assessments of 
adherence such as unannounced pill counts or pharmacy refills would have been useful, 
particularly prior to or following discharge from the controlled environment.   
Relatedly, given the controlled environment, there were very high rates of self-
reported adherence in the past four days. This did not allow us to use past four day 
adherence ratios (for missed doses of HAART or other medications) as originally 
intended for recent adherence, and in turn, we relied only on viral load and a broader 
assessment of frequency of reasons endorsed for nonadherence for all medications. 
Although viral load is a recommended objective assessment of adherence, it was limited 
to only the individuals on HAART, which represented a smaller subset of our total 
sample.  
Additionally, although assessing reasons endorsed for nonadherence has been 
suggested to be an effective strategy to minimize social desirability biases and other 
inaccuracies of self-reported adherence (Simoni et al., 2006), there are some significant 





for nonadherence reflects actual missed doses. It may be that some individuals perceive 
greater barriers to adherence and report nonadherence across a range of reasons, whereas 
other individuals may consistently miss more doses but for a single reason. In this case, 
the measurement of frequency of reasons endorsed for nonadherence may not accurately 
reflect number of missed doses. Given the ceiling in rates of self-reported missed doses in 
the current study, we could not accurately assess whether missed doses correlated with 
frequency of reasons for nonadherence. However, even if we had more variability in the 
reporting of missed doses and could examine the correlation between frequency of 
reasons endorsed and missed doses, the noted limitations of assessing missed doses via 
self-report may have still precluded our ability to answer questions regarding the 
accuracy of this measure (Simoni et al., 2006). Viral load and frequency of reasons 
endorsed for nonadherence also were not significantly correlated among individuals on 
HAART (r = .20, p = .21); however, we did not assess frequency of reasons endorsed for 
nonadherence to HAART specifically—which we would hypothesize would be most 
closely related to viral load—and thus including other medication types in our assessment 
of reasons endorsed for nonadherence may explain its lack of correlation with viral load. 
Future studies must examine the accuracy of assessing reasons endorsed for 
nonadherence as a measure of missed doses by comparing it to objective measures of 
adherence. Despite these potential limitations of using reasons endorsed for 
nonadherence as a proxy for adherence behavior, the measure does provide rich clinical 
information about barriers to adherence that is not captured by reporting on missed doses 
or viral load, which has the potential to provide very useful clinical targets in future 





 Other limitations of this measure include the fact that we did not separate 
medication classes when assessing reasons endorsed for missed doses. Most importantly, 
we did not assess frequency of reasons endorsed for nonadherence to HAART 
specifically compared to other medications and instead examined reasons endorsed for 
nonadherence to all daily medications jointly. It is possible that reasons for missed doses 
differ across different medical conditions and medication types; however, the same holds 
true across classes of HAART given differing dosing instructions and side effect profiles. 
By assessing reasons for nonadherence across HAART and other medications for those 
not taking HAART, we run the risk of confounding non-equivalent measures of 
adherence; we would expect this confounding to further reduce the likelihood of 
establishing systematic relationships with other variables, yet we still identified 
meaningful relationships between depressive symptoms, punishment, and reasons 
endorsed for nonadherence. 
Additionally, although in the current study we were interested in adherence to 
other medications to capture adherence behavior among individuals not on HAART, it is 
also very likely that adherence to these other forms of medication, particularly 
antidepressants, may have a direct effect on HAART adherence given reduced depressive 
symptoms following regular antidepressant use. For instance, Horberg et al. (2008) found 
that depressed individuals taking serotonin reuptake inhibitors (SSRIs) showed similar 
rates of HAART adherence as non-depressed individuals. This is consistent with other 
studies demonstrating that treating depression using antidepressants is associated with 
improved medication adherence (Walkup, Wei, Sambamoorthi, & Crystal, 2008). 





antidepressant adherence are highly correlated behaviors, and it may not only be the 
result of antidepressant use that HAART adherence improves. For instance, one study 
showed that mean psychotropic medication adherence over a three-month period was 
significantly associated with greater HAART adherence over the same three-month 
period, and that it may not have been a consequence of the antidepressants that HAART 
adherence was related; rather, that the behaviors were highly correlated (Cruess et al., 
2012). Thus, although there may be limitations in considering adherence to other forms 
of medication as a proxy for HAART adherence, there is also some evidence suggesting 
it may be an accurate indicator. Although ideally we would have been able to assess these 
questions in the current study, we were not able to for a few reasons, including no 
assessment of adherence to antidepressant medications alone, the ceiling in rates of past 
four day adherence ratios, as well as the cross-sectional design. Future work that follows 
participants over time and measures adherence to HAART following initiation or re-
initiation of other medications, specifically antidepressants, would be necessary to 
address these limitations. 
Another primary limitation of the current study related to recruitment criteria. 
Given that the majority of participants were recruited as part of a larger trial not primarily 
focused on medication adherence, not all participants were required to be on HAART. 
The design would have been significantly strengthened if all individuals recruited were 
on HAART, and ideally based on a certain threshold of HAART nonadherence as 
suggested by the CDC recommendations for assessing best practices in HIV medication 
adherence research (Charania, 2010). Yet, one could also argue that by recruiting 





HIV/AIDS outcomes (CDC, 2011a). Additionally, given the extremely high rates of non-
use and starting and stopping HAART among substance users, only including participants 
on HAART may have significantly limited our sample and may have reduced potential 
for generalizability to other samples. In sum, by recruiting all individuals and assessing 
adherence to other medications for individuals not on HAART, we were able to test our 
model using a very high risk sample that may be most representative of low-income, 
minority substance users living with HIV/AIDS. However, to test this model for HAART 
adherence specifically, future work should recruit based on specific parameters related to 
HAART use.  
Finally, the current study only tested one specific mechanism according to a 
strictly behavioral theoretical framework; future work may consider testing more 
elaborate mediational models that incorporate other potential explanatory mechanisms, 
for instance cognitive and neurocognitive variables that are related to adherence to 
HAART and other forms of medication (Hinkin et al., 2004; Stilley, Sereika, Muldoon, 
Ryan, & Dunbar-Jacob, 2004). However, it is important to note that this focus on 
behavioral theories was an important consideration, as the most commonly endorsed 
reasons for nonadherence are behavioral (Palmer et al., 2003). Additionally, these 
behavioral variables align closely with the treatment targets of existing integrated 
interventions for addressing depression and adherence; as such, the current findings may 
be useful for spurring future efforts to continue to improve parsimony of these 
interventions (Daughters et al., 2010; Safren et al., 2012).  






Despite the noted limitations of the current study, the findings are an important 
first step to test potential mediators of the relationship between depression and 
medication adherence and have important implications in improving our understanding of 
a potential mechanism by which depression may impact adherence. By pinpointing 
specific processes through with depression relates to adherence, we can develop targeted 
interventions and improve efficacy and parsimony of existing interventions. If findings 
continue to replicate, this may suggest adapting existing interventions for depression and 
adherence among substance users to focus more exclusively on reducing punishment in 
one’s environment and the impact punishment may have on one’s perceived self-efficacy 
to adhere to medication regimens. For instance, cognitive behavioral interventions have 
been developed to simultaneously target depressive symptoms and improve medication 
adherence among substance users with HIV/AIDS  (Daughters et al., 2010; Safren et al., 
2012); these interventions target punishment to some degree (i.e., psycho-education 
regarding one’s control over their health condition through self-care and HAART 
adherence), and perhaps findings support the notion that these interventions should more 
directly target perceptions or experiences of punishment that may interfere with 
adherence. Additionally, findings may also inform screening tools, such that individuals 
reporting greater levels of punishment may be identified and enrolled in targeted 
interventions to prevent future nonadherence. Prevention interventions focusing on 
punishment may similarly incorporate psycho-education regarding the control individuals 
have over their health condition through adherence, as well as openly discussing potential 





punishing experiences one may encounter when taking HAART can be anticipated and 
normalized. 
 In sum, findings support the need for targeting perceptions of punishment as a 
potential means to improve medication adherence, yet future research is necessary to 
address existing study limitations. Future studies should incorporate larger sample sizes, 
longitudinal designs, more objective measures of medication adherence, and recruit in an 
outpatient or non-treatment seeking sample based on HAART use. Future work may also 
consider other potential mediators and contrast indirect effects to test whether 
punishment does indeed explain this relationship over and above other relevant factors. 
Despite the limitations, current findings are important in improving our understanding of 
a potential mechanism by which depression may impact medication adherence. 
Additionally, focusing on adherence behaviors even among HIV-infected individuals not 
on HAART addresses the needs of a group most at risk for poor HIV/AIDS outcomes. 
These findings represent a first step in improving our understanding of how depression 
may relate to medication nonadherence among HIV-infected substance users at high risk 
for poor health outcomes. It is the hope that these findings will spur efforts for continued 









Demographic information and Axis I and II psychopathology for total sample and 
comparing groups based on HAART status. 
 
 
Overall                       
(n = 73) 
On HAART               
(n = 47) 
     Not on HAART                    
(n = 26) Statistic p value 
Demographics      
Age, mean (SD) 45.1 (7.8) 45.8 (7.9) 45.0 (8.8) t(71) = 0.40 .69 
Gender    χ
2 
(2) = 3.06 .22 
Male, % 41.1 45.7 26.9   
Female, % 50.7 47.8 61.5   
Transgender, % 8.2 6.5 11.5   
Marital Status    χ
2 
(2) = 1.22 .54 
     Single, %   62.7 58.7 73.1   
     Separated/divorced, %   26.7 30.4 19.2  
     Married, %   9.3 10.9 7.7  
Race/ethnicity    χ
2 
(3) = 3.48 .32 
     White, %   1.3 2.1 0.0   
     Black, %   94.5 93.6 96.4  
     Hispanic , %   2.7 4.3 0.0  
     Native American, %   1.4 0.0 3.6  
Heterosexual, % 71.2 73.9 71.4 χ
2 
(2) = 0.09 .96 
≤ High school/GED, %   78.7 78.7 78.6 χ
2 
(1) = 0.00 .99 
Total Annual Income <$10,000, %      78.7 80.9 75.0 χ
2 
(1) = 0.36 .55 
Unemployed, %   89.3 85.1 96.4 χ
2 
(1) = 2.36 .12 
Psychopathology*       
Current MDD, % 17.8 15.9 23,1 χ
2 
(1) = 0.56 .46 
Lifetime MDD, % 45.2 51.1 28.6 χ
2 
(1) = 1.25 .26 
Bipolar I, % 15.1 11.1 23.1 χ
2 
(1) = 1.80 .18 
Lifetime PTSD, % 19.2 20.0 22.2 χ
2 
(1) = 0.02 .96 
Crack/cocaine dependence (past year), % 54.8 48.9 60.7 χ
2 
(1) = 1.81 .18 
Alcohol dependence (past year), % 32.9 30.4 35.7 χ
2 
(1) = 0.69 .41 
Opioid (heroin) dependence (past year), % 24.7 24.4 25.0 χ
2 
(1) = 0.03 .86 
ASPD 27.8 28.9 28.0 χ
2 






     *All Axis I and II diagnoses with ≥15% prevalence in current sample are listed. MDD = Major Depressive Disorder. PTSD = Posttraumatic Stress 
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Health Status      
CD4 Count, mean (SD) 448.46 (247.11) 431.00 (248.37) 492.11 (245.39) t(61) = -.89 .38 
Years since HIV diagnosis, mean (SD) 10.88 (10.75) 10.74 (6.99) 11.26 (9.24) t(61) = -.23 .82 
SF-36 (PCS) 58.77(10.75) 59.25 (11.05) 57.91 (10.36) t(70) = .51 .61 
SF-36 (MCS) 59.79 (13.13) 59.87 (11.16) 59.66 (16.23) t(70) = .06 .95 
Health Care-Related Factors       
Has a PCP, % 97.26 97.87 96.15 χ2 (1) = .17 .60 
Has a health insurance plan, % 95.89 95.74 96.15 χ2 (1) = .01 .71 
 
Overall                       
(n = 73) 
On HAART               
(n = 47) 
Not on HAART      
(n = 26) Statistic 
      p  
value 





Table iii  
 
Levels of IV (depressive symptoms), mediators (goal-directed activation and 
reinforcement/punishment), and DV (medication adherence, viral load) for total sample 
and by HAART status.  
 
 
  Overall                                               
(n = 73) 
On HAART               
(n = 47) 
Not on HAART                     
(n = 26) Statistic p value 
Depressive symptoms      
BDI-II 13.54 (11.00) 13.49 (11.70) 13.62 (9.89) t(69) = -.05 .96 
HAMD 2.99 (3.32) 2.86 (3.45) 3.20 (3.12) t(67) = -.40 .69 
Mediators       
BADS-AC 23.08 (10.27) 21.48 (10.79) 25.92 (8.77) t(70) = -1.79 .08 
BADS-AR 23.22 (12.46) 23.74 (12.19) 22.31 (13.13) t(70) = .47 .64 
BADS-WS 20.03 (7.52) 22.13 (7.59) 21.85 (7.52) t(70) = .15 .88 
BADS-SI 20.03 (7.48) 20.22 (7.92) 19.69 (6.76) t(70) = .28 .78 
BADS-Tot 88.36 (25.92) 87.57 (27.22) 89.77 (23.90) t(70) = -.34 .73 
RPI-Reward 34.29 (6.10) 34.11 (6.51) 34.62 (5.42) t(70) = -.34 .74 
RPI-Punish 21.46 (4.57) 21.57 (3.99) 21.27 (5.53) t(70) = .26 .79 
RPI-Tot 55.75 (8.27) 55.67 (7.67) 55.88 (6.29) t(70) = -.10 .92 
Medication Adherence       
ACTG-reasons 11.97 (9.42) 12.37 (9.39) 11.18 (9.67) t(63) = .48 .63 
Log10VL 2.42 (1.08) 1.98 (.83) 3.50 (.84) t(63) = -6.56 .001 
      












BADS-AC = Behavioral Activation for Depression Scale, Activation Subscale; BADS-AR = Avoidance/Rumination Subscale; BADS-WS = 
Work/School Impairment Subscale; BADS-SI = Social Impairment Subscale; BADS-tot = Total Score; RPI-Reward = Reward Probability Index, 
Reward Probability Subscale; RPI-Punishment = Environmental Suppressors Subscale; RPI-Total = Total Score; ACTG-reasons = total frequency 
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Frequency of reasons for nonadherence:         
Total sample (n = 73) 
Viral load (log10 transformed): 
Individuals on HAART (n = 47) 
 Statistic p value  Statistic p value  
Demographics     
Age, mean (SD) r = -.07  .56 r = .03  .85 
Gender F(2, 65) = 1.55 .22 F(1, 43) = .46 .50 
Marital Status F(4, 63) = .43 .78 F(4, 40) = 2.32 .07 
Race/ethnicity  F(3, 64) = 1.03 .39 F(2, 42) = .42 .66 
≤ High school/GED, %   F(1, 66) = .14 .71 F(1, 43) = .02 .88 
Total Annual Income <$10,000, %      F(1, 66) = .03 .86 F(1, 43) = .33 .57 
Unemployed, %   F(1, 66) = .65 .42 F(1, 43) = .30 .59 
Health Status     
CD4 Count r = -.14 .28 r = .32 .03 
Years since HIV diagnosis       r = .10 .47 r = -.10 .53 
SF-36 (PCS)   r = .10 .43 r = -.18 .24 





Correlation matrix of depressive symptoms, potential mediators, and medication adherence (self-reported reasons for all 
medications missed) for all participants (n = 73).  
 
 1   2   3    4   5    6      7   8  9 10   11 
1. BDI-II -- .52*** -.08 -.37*** -.45*** -.38*** -.46*** -.36** -.22 -.39***  .12 
2. HAMD  -- -.14 -.26* -.35** -.19 -.34** -.31** -.26* -.38**  .26* 
3. BADS-AC   -- -.07  .09  .03  .40***  .34**  .23  .38*** -.03 
4. BADS-AR    --  .56***  .68***  .81***  .16  .38***  .33** -.16 
5. BADS-WS      --  .60***  .77***  .40***  .37**  .50*** -.18 
6. BADS-SI        --  .80***  .34**  .38***  .46*** -.24 
7. BADS-Tot         --  .42***  .49***  .59*** -.21 
8. RPI-Reward         --  .17  .84*** -.15 
9. RPI-Punish           --  .68*** -.39*** 
10. RPI-Tot            -- -.32* 
11. ACTG reasons             -- 
 
  







Correlation matrix of depressive symptoms, potential mediators, and viral load for participants on HAART (n = 47). 
 
 1   2   3    4   5    6    7   8   9 10   11 
1. BDI-II -- .45*** -.07 -.47*** -.48*** -.50*** -.52*** -.40** -.30* -.49***  .08 
2. HAMD   -- -.07 -.30 -.32* -.20 -.31* -.33* -.24 -.41**  .20 
3. BADS-AC    --  .03  .11  .15  .48***  .26  .30*  .37*  .06 
4. BADS-AR     --  .57***  .65***  .81***  .25  .44**  .43** -.07 
5. BADS-WS      --  .60***  .75***  .43**  .30*  .52*** -.26 
6. BADS-SI        --  .81***  .48***  .41**  .62*** -.20 
7. BADS-Tot         --  .47***  .52***  .67*** -.14 
8. RPI-Reward          --  .01  .85*** -.09 
9. RPI-Punish           --  .53***  .16 
10. RPI-Tot            --  .01 












Testing the indirect effect of punishment based on 5,000 bootstrapped samples.  
 
Indirect effect  Boot Bias SE 
     Punishment .23 .009 .15 
Percentile-Based 95% CI LL UL  
Punishment .01 .59  
Bias-Corrected 95% CI LL UL  
Punishment .03 .64  
 
IV = HAMD; DV = Frequency of reasons endorsed for medication nonadherence using ACTG; Mediator = 








Comparing individuals on HAART based on detectable viral load status: examining 
differences in depression and potential mediators.  
 
 VL ≤ 50 
(n = 21) 
VL > 50 
(n = 24) 
  
 Mean (SD)   Mean (SD)    Statistic p value  
BDI-II 11.62 (10.92) 15.48 (12.48) t(42) = -1.09 .28 
HAMD   2.85 (3.66)    3.00 (3.37) t(41) = -.14 .89 
BADS-AC 21.05 (11.89) 22.25 (10.01) t(43) = -.37 .72 
BADS-AR 25.62 (12.75) 21.33 (11.20) t(43) = 1.20 .24 
BADS-WS 23.52 (6.66) 20.72 (8.42) t(43) = 1.14 .26 
BADS-SI 21.81 (7.64) 18.67 (8.16) t(43) = 1.33 .19 
BADS-Tot 92.00 (28.97) 83.17 (25.98) t(43) = 1.08 .29 
RPI-Reward 34.71 (7.39) 33.54 (5.89) t(43) =  .59 .56 
RPI-Punish 21.05 (4.42) 21.96 (3.69) t(43) = -.75 .45 
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Note. * p < .05 ** p < .01, *** p < .001 
βa = standardized beta coefficient of the IV -> the mediator; βb = standardized beta coefficient for the 
mediator -> DV with IV in the model 
βc = standardized beta coefficient for the IV with mediator in the model; βd = standardized beta coefficient 
















βb = -.35** 










Daily Activities and HIV Medication Adherence 
A series of studies have examined the impact of “daily routinization,” defined as 
the extent to which one’s daily life is structured, in relation to HIV medication adherence. 
Ryan & Wagner (2003) first conducted an exploratory, qualitative study in which they 
interviewed 27 HIV positive individuals with drug abuse histories (past or current) to 
examine circumstances surrounding missed doses (54% of the sample consisted of active 
drug users, and 36% had clinical depression). The study focused on “episodic” rather 
than “global” adherence patterns (focusing on specific times an individual misses) to 
have a more in-depth understanding of factors influence nonadherence patterns. The 
primary themes that emerged across all interviews were the extent to which participants 
“routinized” their pill regimen and the specific factors that influenced routinization. Their 
conclusions suggest that the degree of structure in one’s environment and factors 
associated with ability to maintain these routines play an important role in successful 
adherence.  
However, their study also identified that “hectic days filled with errands, chores” 
could also be associated with nonadherence due to exhaustion. “Being out, whether 
running errands, visiting friends, going to meetings or appointments” were associated 
with missing doses, and the activities may act as a “double-edged sword” providing 
structure and stability, yet also increasing fatigue and chaos associated with 
nonadherence. A salient quote from their interviews well-captures the issue: “too many 
things and I forget the most important thing—my medications.” Many individuals felt 





but also “an even bigger and more important goal,” “a person has to make up their mind 
about what is important to them.”  
Regarding substance use, their findings suggested that substance use and 
nonadherence were not always directly correlated; rather, there was often a more indirect 
or delayed effect of substance use on the environment that was associated with 
nonadherence, rather than being a direct cause of missed doses. Findings indicated that it 
was difficult to attribute missed doses to a specific incident of drug use, but rather more 
about how drug use is tied into and affects daily routine through environmental and 
behavioral pattern disruptions. This study offered great insight into this key behavioral 
factor influencing adherence; yet, authors acknowledge a key barrier in moving forward 
to a quantitative, empirical investigation of this relationship: “no established methods for 
reliably assessing routinization” (Ryan & Wagner, 2003). 
As such, as a follow up study to this initial qualitative study, Wagner & Ryan 
(2004) conducted a quantitative study aiming to further investigate the relationship 
between routinization of daily behaviors and activities in relation to adherence among 
HIV-positive drug users and to develop an assessment measure of the construct of 
routinization. The assessment they developed of routinization of daily activities examined 
specific categories of activities, and participants reported how often they engaged in each 
of 14 behaviors related to meals, responsibilities (work, errands, appointments), 
socializing (visit friends inside or outside house, attend meetings/support groups), 
watching a favorite TV program, and staying overnight in other locations. Authors also 
utilized a more generalized 9-item measure of the degree of structure and organization in 





time”) that had been developed by their team in previous research (Wagner, Remien, 
Deloezal, & Carballo-Dieguez, 2002). They recruited 51 participants with a history of 
drug dependency (past or current). The sample was 90% male, racially diverse (33% 
White, 43% Black), 22% were employed, 47% had some college, and 65% had stable 
housing. Regarding substance use, 47% had used illicit drugs in the past month, 39% had 
a current drug dependency, and regarding depression, 25% met criteria for a depressive 
mood disorder. 
Their findings demonstrated that a high frequency of four daily activities: eating 
breakfast, watching a favorite television program, attending meetings, and sleeping at 
home were significantly associated with high levels of adherence. A lower frequency of 
having friends over to visit was associated with higher adherence. A composite score that 
took into account how much a patient’s daily routine incorporated these specific 
behaviors was significantly associated with adherence (r = .63). In a final regression 
model, daily routinization predicted over and above all other independent variables 
associated with adherence (gender, diagnostic status (drug dependency and depression), 
patient-provider relationship, and perceived treatment efficacy) and accounted for 36% of 
the variance in predicting adherence. None of the other variables independently 
associated with adherence were significant predictors of adherence in the larger model, 
demonstrating that routinization of daily activities predicted nonadherence over and 
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